



(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(43) Date of publication:
20.05.2020 Bulletin 2020/21

(51) Int Cl.:
C12Q 1/686 (2018.01) **C12Q 1/6827** (2018.01)
C12N 9/12 (2006.01)

(21) Application number: **18832513.8**

(86) International application number:
PCT/KR2018/006246

(22) Date of filing: **31.05.2018**

(87) International publication number:
WO 2019/013451 (17.01.2019 Gazette 2019/03)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(72) Inventors:
• **LEE, Byung Chul**
Hanam-si
Gyeonggi-do 12909 (KR)
• **PARK, Il Hyun**
Hanam-si
Gyeonggi-do 12915 (KR)
• **LEE, Huy Ho**
Seongnam-si
Gyeonggi-do 13361 (KR)


(30) Priority: **12.07.2017 KR 20170088373**
12.07.2017 KR 20170088376

(74) Representative: **Dehns**
St. Bride's House
10 Salisbury Square
London EC4Y 8JD (GB)

(71) Applicant: **Genecast Co., Ltd.**
Seongnam-si, Gyeonggi-do 13403 (KR)

(54) **DNA POLYMERASE WITH INCREASED GENE MUTATION SPECIFICITY AND PCR BUFFER COMPOSITION FOR INCREASING ACTIVITY THEREOF**

(57) The present invention relates to a DNA polymerase having increased gene mutation specificity and a PCR buffer composition for increasing activity of the DNA polymerase. More specifically, provided, in the present invention, are a DNA polymerase in which a mutation is induced at a specific amino acid position to increase gene mutation specificity, a nucleic acid sequence encoding the polymerase, a vector comprising the nucleic acid sequence, and a host cell transformed with the vector. In addition, provided are a method for *in vitro* detecting one or more gene mutations or SNPs in one or more templates by using a DNA polymerase having increased gene mutation specificity, a composition for detecting a gene mutation or SNP comprising the DNA polymerase, and a PCR kit comprising said composition. Furthermore, provided are a PCR buffer composition for increasing the activity of a DNA polymerase having increased gene mutation specificity, a PCR kit for detecting a gene mutation or SNP comprising the PCR buffer composition and/or the DNA polymerase having increased gene mutation specificity, and a method for *in vitro* detecting one or more gene mutations or SNPs in one or more templates by using the kit.



Description

[Technical Field]

5 **[0001]** The present invention relates to a DNA polymerase with increased gene variation specificity and a PCR buffer composition for increasing the activity thereof, and more specifically, a DNA polymerase with increased gene variation specificity due to a mutation occurring at a specific amino acid position, a nucleic acid sequence encoding the polymerase, a vector including the nucleic acid sequence and a host cell transformed with the vector, a method of *in vitro* detecting one or more gene variations or SNPs in one or more templates using the DNA polymerase with increased gene variation specificity, a composition for detecting a gene variation or SNP, which includes the DNA polymerase, and a polymerase chain reaction (PCR) kit including the composition.

10 **[0002]** Moreover, the present invention provides a PCR buffer composition for increasing the activity of the DNA polymerase with increased gene variation specificity, a PCR kit for detecting a gene variation or SNP, which includes the PCR buffer composition and/or the DNA polymerase with increased gene variation specificity, and a method of *in vitro* detecting one or more gene variations or SNPs in one or more templates using the kit.

[Background Art]

20 **[0003]** Since the first human genomic sequence has been defined, the inventors have focused on finding the genetic difference among individuals, such as single nucleotide polymorphisms (SNPs). SNPs in a genome are of interest because it is more and more clear that they are associated with different drug resistances or predisposing factors for various diseases. Due to the subsequent knowledge of medically-related nucleotide variation, a therapeutic method for the genetic supply of an individual may be applied, and a drug therapy which is ineffective or causes a side effect may be prevented. The development of technology that enables time- and cost-effective identification of nucleotide variation will bring further advances in pharmacogenetics.

25 **[0004]** SNPs account for the major genetic variations in a human genome and cause 90% or more of differences between individuals. To detect other nucleic acid variations such as the genetic variations and mutations, various methods may be used. For example, the identification of a variant of a target nucleic acid may be accomplished by hybridizing a nucleic acid sample to be analyzed with a hybridization primer specific for a sequence variant under suitable hybridization conditions.

30 **[0005]** However, it was found that such a hybridization method cannot satisfy clinical needs, particularly, in terms of sensitivity, which is required for an assay. Therefore, PCR has been extensively used in molecular biology and a diagnostic testing method for detecting mutations such as SNPs and other allelic sequence variants. Here, in consideration of the presence of a variant, a target nucleic acid to be tested was amplified by polymerase chain reaction (PCR) before hybridization. As a hybridization probe for the assay, generally, a single-stranded oligonucleotide is generally used. A modified embodiment of the assay includes a fluorescent hybridization probe. Generally, efforts have been made to automate methods of measuring SNPs and other sequence variations (Gut, Hum. Mutat. 17, 475-492 (2001)).

35 **[0006]** An alternative to sequence variation-specific hybridization known in the art is provided by so-called gene variation-specific amplification. In this detection method, during amplification, a variation-specific amplification primer is used, and generally has a so-called differential terminal nucleotide residue at the 3' end of the primer, where the residue is only complementary for one specific variation of a target nucleic acid to be detected. In this method, the nucleotide variant is measured by the presence or absence of a DNA product after PCR amplification. The principle of gene variation-specific amplification is based on the formation of a canonical or non-canonical primer-template complex at the end of a gene variation-specific amplification primer. Precisely, at the 3' end of the paired primer, amplification occurs by a DNA polymerase, but at the mismatched primer end, extension is suppressed.

40 **[0007]** For example, U.S. Pat. No. 5,595,890 discloses a method for gene variation-specific amplification and its application thereof, for example, the application to detect clinically associated point mutation in a k-ras tumor gene. In addition, U.S. Pat. No. 5,521,301 discloses an allele-specific amplification method for genotyping of an ABO blood group system. In contrast, U.S. Pat. No. 5,639,611 discloses the use of allele-specific amplification associated with the detection of a point mutation that causes sickle cell anemia. However, gene variation-specific amplification or allele-specific amplification is problematic in that it has low selectivity, and thus a more complicated and time- and cost-intensive optimizing step is needed.

45 **[0008]** Such a method for detecting sequence variations, polymorphisms and mainly point mutations requires allele-specific amplification (or gene variation-specific amplification) particularly when a sequence variation to be detected is deficient compared to dominant variations in the same nucleic acid fragment (or the same gene).

50 **[0009]** For example, this situation occurs when sporadic tumor cells are detected in the body fluid such as blood, serum or plasma by gene variation-specific amplification (U.S. Pat. No. 5,496,699). To this end, DNA is first isolated from the body fluid such as blood, serum or plasma, and DNA is derived from deficient, sporadic tumor cells and excessive

non-proliferative cells. Thus, mutations that are significant to tumor DNA in the k-ras gene should be detected from several copies in the presence of an excessive amount of wild-type DNA.

[0010] All methods for gene variation-specific amplification disclosed in the prior art have the disadvantage that a 3'-terminal differential oligonucleotide residue should be used. In addition, despite the use of a 3'-differential nucleotide residue, these methods have the disadvantage that primer extension occurs at low levels in the presence of a suitable DNA polymerase even when a target nucleic acid is not exactly matched with a sequence variant to be detected. Particularly, when a specific sequence variant is detected by an excessive background nucleic acid including a different sequence variant, it leads to a false positive result. The main reason for the disadvantage of the PCR-based method is the incompatibility of a polymerase used in the method for sufficiently differentiating mismatched bases. Therefore, it is not yet possible to directly obtain clear data on the presence or absence of a mutation by PCR. To date, additional time- and cost-intensive purification and analysis methods have been required for the clear diagnosis of mutations. Therefore, a novel method for improving the selectivity of gene variation- or allele-specific PCR amplification will greatly affect the reliability and robustness of direct gene variation or SNP analysis by PCR.

[0011] Therefore, there are continuous demands for the development of a DNA polymerase with increased gene variation specificity and an optimal reaction buffer in which various materials are mixed to exhibit a proper function of the DNA polymerase.

[0012] The inventors had made efforts to develop a novel DNA polymerase that can improve the selectivity of gene variation-specific PCR amplification and a reaction buffer for increasing its activity, confirming that gene variation specificity significantly increased when a mutation occurs at an amino acid residue at a specific position of Taq polymerase, and the activity of the DNA polymerase with increased gene variation specificity increases when the concentration of KCl, $(\text{NH}_4)_2\text{SO}_4$ and/or tetra methyl ammonium chloride (TMAC) among the components of the PCR buffer composition is adjusted, and thus the present invention was completed.

[Disclosure]

[Technical Problem]

[0013] The present invention is directed to providing a DNA polymerase for detecting one or more gene variations or SNPs in a target sequence having a gene variation or SNP.

[0014] The present invention is also directed to providing a nucleic acid sequence encoding the DNA polymerase according to the present invention, a vector including the nucleic acid sequence, and a host cell transformed with the vector.

[0015] The present invention is also directed to providing a method of preparing the DNA polymerase according to the present invention.

[0016] The present invention is also directed to providing a method of *in vitro* detecting one or more gene variations or SNPs in one or more templates using the DNA polymerase of the present invention.

[0017] The present invention is also directed to providing a composition for detecting a gene variation or SNP, which includes the DNA polymerase of the present invention.

[0018] The present invention is also directed to providing a kit for detecting the DNA polymerase of the present invention, which includes the composition for detecting a gene variation or SNP according to the present invention.

[0019] The present invention is also directed to providing a PCR buffer composition for increasing the activity of a DNA polymerase with increased gene variation specificity.

[0020] The present invention is also directed to providing a PCR kit for detecting a gene variation or SNP, which includes the PCR buffer composition and/or the DNA polymerase with increased gene variation specificity according to the present invention.

[0021] The present invention is also directed to providing a method of *in vitro* detecting one or more gene variations or SNPs in one or more templates using the PCR kit according to the present invention.

[Technical Solution]

[0022] One aspect of the present invention provides a DNA polymerase comprising a Taq polymerase amino acid sequence of SEQ ID NO: 1, the DNA polymerase including

(a) a substitution at amino acid residue 507 in the amino acid sequence of SEQ ID NO: 1; and

(b)

(i) a substitution at amino acid residue 536 in the amino acid sequence of SEQ ID NO: 1,

(ii) a substitution at amino acid residue 660 in the amino acid sequence of SEQ ID NO: 1,

- (iii) substitutions at amino acid residues 536 and 660 in the amino acid sequence of SEQ ID NO: 1, or
- (iv) substitutions at amino acid residues 536, 587 and 660 in the amino acid sequence of SEQ ID NO: 1.

[0023] According to an exemplary embodiment of the present invention, the substitution at the amino acid residue 507 may be a substitution of glutamic acid (E) with lysine (K), the substitution at the amino acid residue 536 is a substitution of arginine (R) with lysine (K), the substitution at the amino acid residue 587 is a substitution of arginine (R) with isoleucine (I), and the substitution at the amino acid residue 660 is a substitution of arginine (R) with valine (V).

[0024] According to another exemplary embodiment of the present invention, the DNA polymerase may discriminate a matched primer from a mismatched primer, wherein the matched primer may be hybridized with the target sequence, and the mismatched primer may have a non-canonical nucleotide at the 3' end thereof with respect to the hybridized target sequence.

[0025] According to still another exemplary embodiment of the present invention, the DNA polymerase may exhibit a Ct value lower than the amplification of the target sequence comprising the mismatched primer.

[0026] Another aspect of the present invention provides a nucleic acid sequence encoding the DNA polymerase according to the present invention, a vector including the nucleic acid sequence, and a host cell transformed with the vector.

[0027] Still another aspect of the present invention provides a method of preparing a DNA polymerase, which includes: culturing the host cells; and isolating a DNA polymerase from the cell culture and a supernatant thereof.

[0028] Yet another aspect of the present invention provides a method of *in vitro* detecting one or more gene variations or SNPs in one or more templates, the method including:

bringing the DNA polymerase according to the present invention into contact with

- a) one or more templates;
- b) one or more matched primers, one or more mismatched primers or both of one or more matched primers and one or more mismatched primers; and
- c) a nucleoside triphosphate,

wherein the one or more matched primers and the one or more mismatched primers are hybridized with a target sequence, and the mismatched primer has a non-canonical nucleotide at base position 7 from the 3' end thereof with respect to the hybridized target sequence.

[0029] According to an exemplary embodiment of the present invention, the method may include a melting point analysis using a double strand-specific dye.

[0030] According to another exemplary embodiment of the present invention, the method may be accomplished by real-time PCR, the analysis on agarose gel after standard PCR, gene variation-specific amplification or allele-specific amplification through real-time PCR, tetra-primer amplification-refractory mutation system PCR or isothermal amplification.

[0031] Yet another aspect of the present invention provides a composition for detecting a gene variation or SNP, comprising the DNA polymerase according to the present invention.

[0032] Yet another aspect of the present invention provides a PCR kit including the composition for detecting a gene variation or SNP.

[0033] According to one exemplary embodiment of the present invention, the PCR kit may be used in competitive allele-specific TaqMan PCR (cast PCR), droplet digital PCR or MassARRAY.

[0034] According to another exemplary embodiment of the present invention, the PCR kit may further include one or more matched primers, one or more mismatched primers or both of one or more matched primers and one or more mismatched primers, where the one or more matched primers and the one or more mismatched primers may be hybridized with a target sequence, and the mismatched primer may have a non-canonical nucleotide at base position 7 from the 3' end thereof with respect to the hybridized target sequence.

[0035] According to still another exemplary embodiment of the present invention, the PCR kit may further include a nucleoside triphosphate.

[0036] According to yet another exemplary embodiment of the present invention, the PCR kit may further include

- a) one or more buffers;
- b) a quantification reagent binding to double-stranded DNA;
- c) a polymerase blocking antibody;
- d) one or more control values or control sequences; and
- e) one or more templates.

[0037] Yet another aspect of the present invention provides a PCR buffer composition for increasing the activity of a DNA polymerase with increased gene variation specificity, which includes 25 to 100 mM KCl; and 1 to 15 mM $(\text{NH}_4)_2\text{SO}_4$, wherein the final pH is 8.0 to 9.0.

[0038] According to one exemplary embodiment of the present invention, the KCl concentration may be 60 to 90 mM.

[0039] According to another exemplary embodiment of the present invention, the $(\text{NH}_4)_2\text{SO}_4$ concentration may be 2 to 8 mM.

[0040] According to still another exemplary embodiment of the present invention, the KCl concentration may be 70 to 80 mM, and the $(\text{NH}_4)_2\text{SO}_4$ concentration may be 4 to 6 mM.

[0041] Yet another aspect of the present invention provides a PCR buffer composition for increasing the activity of a DNA polymerase with increased gene variation specificity, which includes 5 to 80 mM TMAC in the above-described PCR buffer composition.

[0042] According to one exemplary embodiment of the present invention, the KCl concentration may be 40 to 90 mM.

[0043] According to another exemplary embodiment of the present invention, the $(\text{NH}_4)_2\text{SO}_4$ concentration may be 1 to 7 mM.

[0044] According to still another exemplary embodiment of the present invention, the TMAC concentration may be 15 to 70 mM, the KCl concentration may be 50 to 80 mM, and the $(\text{NH}_4)_2\text{SO}_4$ concentration may be 1.5 to 6 mM.

[0045] According to yet another exemplary embodiment of the present invention, the PCR buffer composition may further include Tris Cl and MgCl_2 .

[0046] Yet another aspect of the present invention provides a PCR kit for detecting a gene variation or SNP, which includes the above-described PCR buffer composition.

[0047] According to one exemplary embodiment of the present invention, the PCR kit may include a DNA polymerase comprising a Taq polymerase amino acid sequence of SEQ ID NO: 1, where the DNA polymerase has the substitution(s) of the following amino acids:

- (a) a substitution at amino acid residue 507 in the amino acid sequence of SEQ ID NO: 1; and
- (b)

- (i) a substitution at amino acid residue 536 in the amino acid sequence of SEQ ID NO: 1,
- (ii) a substitution at amino acid residue 660 in the amino acid sequence of SEQ ID NO: 1,
- (iii) substitutions at amino acid residues 536 and 660 in the amino acid sequence of SEQ ID NO: 1, or
- (iv) substitutions at amino acid residues 536, 587 and 660 in the amino acid sequence of SEQ ID NO: 1.

[0048] According to another exemplary embodiment of the present invention, the substitution at the amino acid residue 507 may be a substitution of glutamic acid (E) with lysine (K), the substitution at the amino acid residue 536 may be a substitution of arginine (R) with lysine (K), the substitution at the amino acid residue 587 may be a substitution of arginine (R) with isoleucine (I), and the substitution at the amino acid residue 660 may be a substitution of arginine (R) with valine (V).

[0049] According to still another exemplary embodiment of the present invention, the PCR kit may further include a) a nucleoside triphosphate; b) a quantification reagent binding to double-stranded DNA; c) a polymerase blocking antibody; d) one or more control values or control sequences; and e) one or more templates.

[0050] Yet another aspect of the present invention provides a method of *in vitro* detecting one or more gene variations or SNPs in one or more templates using the PCR kit of the present invention.

[Advantageous Effects]

[0051] Since the DNA polymerase with increased gene variation specificity according to the present invention has a higher mismatch-to-match extension selectivity than conventional Taq polymerase, reliable gene variation-specific amplification is possible without any substrate modification. The present invention also provides an optimal PCR buffer composition that allows the proper function of a DNA polymerase with increased gene variation specificity to be effectively exhibited, and reliable gene variation-specific amplification is possible by considerably increasing the activity of the DNA polymerase using the DNA polymerase with increased gene variation specificity. Moreover, a kit including a PCR buffer composition and/or the DNA polymerase with increased gene variation specificity according to the present invention can effectively detect a gene variation or SNP, and thus can be usefully applied to the medical diagnosis of a disease and recombinant DNA studies.

[Description of Drawings]

[0052]

FIG. 1 shows a process of preparing Taq DNA polymerases having R536K, R660V and R536K/R660V variations: (a) the schematic representation of fragment PCR and overlap PCR; (b) the result of electrophoresis for amplified products obtained by the fragment PCR; and (c) the result of electrophoresis for amplified products obtained by full-length amplification through overlap PCR.

FIG. 2 shows the result of electrophoresis for a pUC19 vector which is digested with restriction enzymes EcoRI/XbaI and treated with SAP and the purified overlap PCR products of (c) in FIG. 1.

FIG. 3 is the schematic representation of fragment PCR and overlap PCR during the preparation of Taq DNA polymerases having E507K, E507K/R536K, E507K/R660V and E507K/R536K/R660V variations, respectively.

FIG. 4 shows the result of electrophoresis for a pUC19 vector digested with EcoRI/XbaI and then treated with SAP and the purified overlap PCR product of FIG. 3 for gel extraction.

FIG. 5 is the schematic representation of the process of preparing a PCR template by collecting oral epithelial cells.

FIGS. 6a to 6d show the results of AS-qPCR for rs1408799 using Taq polymerases having E507K/R536K, E507K/R660V and E507K/R536K/R660V variations according to the present invention, and Taq polymerase having an E507K variation is used as a control.

FIGS. 7a to 7d show the results of AS-qPCR for rs1015362 using Taq polymerases having E507K/R536K, E507K/R660V and E507K/R536K/R660V variations according to the present invention, and Taq polymerase having an E507K variation is used as a control.

FIGS. 8a to 8d show the results of AS-qPCR for rs4911414 using Taq polymerases having E507K/R536K, E507K/R660V and E507K/R536K/R660V variations according to the present invention, and Taq polymerase having an E507K variation is used as a control.

FIG. 9 shows the process of preparing Taq DNA polymerase having E507K/R536K/R587I/R660V variations: (a) the schematic representation of fragment PCR and overlap PCR; and (b) the result of electrophoresis for the amplified product obtained by the fragment PCR.

FIGS. 10a to 10d show the results of AS-qPCR for a template having an SNP of Q61H in a KRAS gene using a E507K/R536K/R587I/R660V polymerase, wherein FIGS. 10a and 10b show the results obtained using a 24-mer long primer, FIGS. 10c and 10d show the results obtained using a 18-mer long primer, and Taq polymerase having E507K/R536K/R660V variations is used as a control.

FIG. 11 shows the result obtained by AS-qPCR for a template having an SNP of G13D in a KRAS gene using a E507K/R536K/R587I/R660V polymerase, and Taq polymerase having E507K/R536K/R660V variations is used as a control.

FIG. 12 shows the result obtained by AS-qPCR for a template having an SNP of G12S in a KRAS gene using a E507K/R536K/R587I/R660V polymerase, and Taq polymerase having E507K/R536K/R660V variations is used as a control.

FIG. 13 shows the result obtained by AS-qPCR for a template having an SNP of L585R in an EGFR gene using a E507K/R536K/R587I/R660V polymerase, and Taq polymerase having E507K/R536K/R660V variations is used as a control.

FIGS. 14a to 14d are graphs showing the amplification delay effect by mismatch according to the change in KCl concentration of a reaction buffer using E507K, E507K/R536K, E507K/R660V and E507K/R536K/R660V Taq polymerases of the present invention.

FIG. 15 shows the result of electrophoresis for a PCR product obtained by amplification with a constantly fixed $(\text{NH}_4)_2\text{SO}_4$ concentration and various KCl concentrations to confirm the optimal KCl concentration in a reaction buffer.

FIG. 16 shows the result of electrophoresis for a PCR product obtained by amplification with a constantly fixed KCl concentration and various $(\text{NH}_4)_2\text{SO}_4$ concentrations to confirm the optimal $(\text{NH}_4)_2\text{SO}_4$ concentration in a reaction buffer.

FIG. 17 is the graph showing the amplification delay effect by mismatch according to the change in $(\text{NH}_4)_2\text{SO}_4$ concentration in a reaction buffer.

FIGS. 18a and 18b are graphs showing the amplification delay effect by mismatch according to the change in TMAC concentration after KCl and $(\text{NH}_4)_2\text{SO}_4$ concentrations are constantly fixed in a reaction buffer.

FIGS. 19a and 19b are graphs showing the amplification delay effect by mismatch according to the change in KCl concentration after TMAC and $(\text{NH}_4)_2\text{SO}_4$ concentrations are constantly fixed in a reaction buffer.

[Modes of the Invention]

[0053] Hereinafter, the present invention will be described in further detail.

[0054] As described above, to improve the disadvantages of the gene variation-specific amplification method disclosed in the conventional art, there is a continuous demand for the development of a DNA polymerase with increased gene variation specificity and an optimal reaction buffer in which various materials are mixed such that the DNA polymerase can exhibit the proper function, and the development of such a method greatly affects the reliability and robustness of

direct gene variation or SNP analysis by PCR. The inventors had made an effort to develop a novel DNA polymerase capable of improving the selectivity of gene variation-specific PCR amplification and a reaction buffer for increasing its activity, confirming that gene variation specificity significantly increased when a mutation occurs on an amino acid residue at a specific position of Taq polymerase, and the activity of the DNA polymerase with increased gene variation-specific amplification efficiency increases when the concentration of KCl, $(\text{NH}_4)_2\text{SO}_4$ and/or tetra methyl ammonium chloride (TMAC) among the components of the PCR buffer composition is adjusted, and thus the present invention was completed.

[0055] Since the DNA polymerase with increased gene variation specificity according to the present invention has a higher mismatch-to-match extension selectivity than conventional Taq polymerase, reliable gene variation-specific amplification is possible without any substrate modification. The present invention also provides an optimal PCR buffer composition that allows the proper function of a DNA polymerase with increased gene variation specificity to be effectively exhibited, and reliable gene variation-specific amplification is possible by considerably increasing the activity of the DNA polymerase using the DNA polymerase with increased gene variation specificity. Moreover, a kit including a PCR buffer composition and/or the DNA polymerase with increased gene variation specificity according to the present invention can effectively detect a gene variation or SNP, and thus can be usefully applied to the medical diagnosis of a disease and recombinant DNA studies.

[0056] Hereinafter, terms used herein will be defined.

[0057] The "amino acid" refers to any monomer unit that can be incorporated into a peptide, a polypeptide or a protein. The term "amino acid" used herein includes 20 natural or genetically encoded alpha-amino acids as follows: alanine (Ala or A), arginine (Arg or R), asparagine (Asn or N), aspartic acid (Asp or D), cysteine (Cys or C), glutamine (Gln or Q), glutamic acid (Glu or E), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L), lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y), and valine (Val or V).

[0058] Amino acids are typically organic acids, which substituted or unsubstituted amino groups, substituted or unsubstituted carboxyl groups, and one or more side chains or groups, or any analogs of these groups. Exemplary side chains include, for example, thiol, seleno, sulfonyl, alkyl, aryl, acyl, keto, azido, hydroxyl, hydrazine, cyano, halo, hydrazide, alkenyl, alkynyl, ether, borate, boronate, phospho, phosphono, phosphine, heterocyclic, enone, imine, aldehyde, ester, thioacid, hydroxylamine, or any combination thereof.

[0059] Other exemplary amino acids include the following amino acids, but the present invention is not limited thereto: an amino acid including a photoactivatable crosslinking agent, a metal-binding amino acid, a spin-labeled amino acid, a fluorescent amino acid, a metal-containing amino acid, a novel functional group-containing amino acid, an amino acid covalently or non-covalently interacting with another molecule, a photocaged and/or photoisomerizable amino acid, a radioactive amino acid, an amino acid including a biotin or biotin analog, a glycosylated amino acid, an amino acid modified with another carbohydrate, an amino acid including polyethylene glycol or polyether, a heavy atom-substituted amino acid, chemodegradable and/or photodegradable amino acid(s), a carbon-linked sugar-containing amino acid, a redox-active amino acid, an amino thioacid-containing amino acid, and an amino acid including one or more toxic parts.

[0060] Regarding the DNA polymerase of the present invention, the term "mutant" means a recombinant polypeptide including one or more amino acid substitutions, compared to a corresponding naturally-occurring or unmodified DNA polymerase.

[0061] The term "thermostable polymerase (referring to a thermostable enzyme)" has thermal resistance, has sufficient activity to achieve subsequent polynucleotide extension, and is not irreversibly denatured (inactivated) when treated at elevated temperatures for the time required to achieve the denaturation of a double-stranded nucleic acid. As used herein, it is suitable for a reaction such as PCR to be used at a cycling temperature. Herein, irreversible denaturation refers to the permanent and complete loss of enzyme activity. The enzyme activity of the thermostable polymerase refers to the catalysis of a nucleotide combination by a method suitable for the formation of a polynucleotide extension product which is complementary to a template nucleic acid strand. Thermophilic bacteria-derived thermostable DNA polymerases include, for example, DNA polymerases derived from *Hermtoga maritima*, *Thermus aquaticus*, *Thermus thermophilus*, *Thermus flabus*, *Thermodipyliporphis*, *Thermus sp.* Sps17, *Thermus sp.* Z05, *Thermus caldophilus*, *Bacillus caldotenax*, *Thermotoga neopolitana* and *Thermosipo africanus*.

[0062] The term "thermoactive" refers to an enzyme maintaining a catalytic property at temperatures (i.e., 45 to 80 °C) conventionally used in reverse transcription or annealing/extension steps in RT-PCR and/or PCR reactions. The thermostable enzyme is not irreversibly inactivated or denatured when treated at elevated temperatures required for nucleic acid denaturation. The thermoactive enzyme may be thermostable or may not thermostable. The thermoactive DNA polymerase may include, but not limited to, DNA or RNA dependent on thermophilic or mesophilic species.

[0063] The term "host cell" includes single-cellular prokaryotic and eukaryotic organisms (e.g., bacteria, yeast, and actinomycetes) and single cells derived from higher plant, an animal, or both thereof.

[0064] The term "vector" refers to a DNA molecule which is replicable and able to deliver foreign DNA such as a gene to a recipient cell, for example, a plasmid, a phage, or an artificial chromosome. The "plasmid," "vector," or "plasmid vector" used herein may be used interchangeably.

[0065] The term "nucleotide" may be a deoxyribonucleic acid (DNA) or a ribonucleic acid (RNA), which is present in a single strand or double strand, and unless particularly described otherwise, an analog of a natural nucleotide may be included.

[0066] The term "nucleic acid" or "polynucleotide" refers to a DNA or RNA polymer, or a polymer that can correspond to an analog thereof. The nucleic acid may be, for example, a chromosome or chromosome fragment, a vector (e.g., an expression vector), an expression cassette, a naked DNA or RNA polymer, a product of a polymerase chain reaction (PCR), an oligonucleotide, a probe, or a primer, but the present invention is not limited thereto. The nucleic acid may be, for example, a single-stranded, double-stranded, or triple-stranded, but is not limited to any specific length. Unless particularly defined otherwise, a specific nucleic acid sequence includes a complementary sequence in addition to a random sequence noted herein, or encodes the same.

[0067] The "primer" refers to a polynucleotide that can serve as a starting point of nucleic acid synthesis in a template-direction under the conditions for the initiation of the extension of a polynucleotide. Primers may also be used in the process of synthesis mediated by various other oligonucleotides which are included as initiators of *de novo* RNA synthesis and an *in vitro* transcription-related process. Primers are typically single-stranded oligonucleotides (e.g., oligodeoxyribonucleotides). The suitable length of a primer varies typically in the range from 6 to 40 nucleotides, and more typically, 15 to 35 nucleotides, according to the intended use. A short primer molecule generally requires a lower temperature to form a sufficiently stable hybridization complex with a template. A primer is not required to correspond to the exact sequence of a template, but needs to be sufficiently complementary to be hybridized with the template subject to extension. In a specific exemplary embodiment, the term "primer pair" means a primer set comprising a 5'-sense primer which is complementarily hybridized to the 5' end of a nucleic acid sequence to be amplified, and a 3'-antisense primer which is hybridized to the 3' end of the sequence to be amplified. A primer may be labeled, if necessary, by being mixed with a marker to be detected by spectroscopic, photochemical, biochemical, immunochemical or chemical means. For example, a useful marker is as follows: 32P, a fluorescent dye, an electron-dense reagent, an enzyme (conventionally used in ELISA), biotin, or a protein that can be used with hapten and an anti-serum or monoclonal antibody.

[0068] The term "5'-nuclease probe" refers to an oligonucleotide having one or more luminescent markers which are used in a 5'-nuclease reaction for targeting nucleic acid detection. In some exemplary embodiments, for example, a 5'-nuclease probe only has a single luminescent part (e.g., a fluorescent dye or the like). In a specific exemplary embodiment, a 5'-nuclease probe has a self-complementary region to form a hairpin structure under selective conditions. In some exemplary embodiments, a 5'-nuclease probe has two or more markers, and one of the two markers is separated or degraded from the oligonucleotide and then released with an increased radiation intensity. In a specific exemplary embodiment, a 5'-nuclease probe is labeled with two different fluorescent dyes, for example, a 5'-end reporter dye and a 3'-end quencher dye. In some exemplary embodiments, a 5'-nuclease probe is labeled at one or more positions in addition to or other than the ends. When the probe is intact, typically, energy transfer occurs between two fluorescent materials to partially or completely quench fluorescence emitted from a reporter dye. During extension in PCR, for example, a 5'-nuclease probe binding to a template nucleic acid is degraded by the activity of no longer quenching the fluorescence emission of a reporter dye, for example, the 5' or 3'-nuclease activity of Taq polymerase or a different polymerase. In some exemplary embodiments, a 5'-nuclease probe may be labeled with two or more different reporter dyes and a 3'-end quencher dye or a part thereof.

[0069] The term "FRET" or "fluorescence resonance energy transfer" or "Foerster Resonance Energy Transfer" refers to the transfer of energy between two or more chromophores, donor chromophores and recipient chromophores (referred to as quenchers). Typically, when a donor is excited by radiating light with an appropriate wavelength, energy is transferred to a recipient. The recipient typically re-radiates energy transferred in the form of light radiated with a different wavelength. When the recipient is a "dark" quencher, it disperses energy transferred in a form other than light. Whether a specific fluorescent material serves as a donor or recipient is dependent on the properties of other members of the FRET pair. Conventionally used donor-recipient pairs include a FAM-TAMRA pair. Conventionally used quenchers are DABCYL and TAMRA. Conventionally used dark quenchers are as follows: BlackHole Quenchers (BHQ), (Biosearch Technologies, Inc., Novato, Cal.), Iowa Black (Integrated DNA Tech., Inc., Coralville, Iowa), and BlackBerry Quencher 650 (BBQ-650) (Berry & Assoc., Dexter, Mich.).

[0070] The term "conventional" or "natural" used to describe a nucleic acid base, a nucleoside triphosphate or a nucleotide refers to those naturally occurring in the polynucleotides described herein (i.e., for DNA, dATP, dGTP, dCTP and dTTP). In addition, dITP and 7-deaza-dGTP are frequently used instead of dGTP, and may be used instead of dATP in an *in vitro* DNA synthesis reaction such as sequencing.

[0071] The term "unconventional" or "modified" used to describe a nucleic acid base, a nucleoside triphosphate or a nucleotide refers to the modification, derivative or analog of a conventional base, nucleoside or nucleotide, which naturally occurs in a specific polynucleotide. A specific, unconventional nucleotide is modified at the 2' position of the ribose, compared with conventional dNTP. Therefore, although a nucleotide naturally occurring in RNA is a ribonucleotide (i.e., ATP, GTP, CTP, UTP, and collectively, rNTP), since the nucleotide has a hydroxyl group at the 2' position of the sugar, compared with dNTP having no hydroxyl group, as used herein, the ribonucleotide is a nucleotide which is not conven-

tionally used as a substrate for a DNA polymerase. As used herein, an unconventional nucleotide includes a compound used as a terminator for nucleic acid sequencing, but the present invention is not limited thereto. An exemplary terminator compound includes a compound having a 2',3'-dideoxy structure, but the present invention is not limited thereto, and is referred to as a dideoxynucleoside triphosphate. Dideoxynucleoside triphosphates such as ddATP, ddTTP, ddCTP and ddGTP are collectively referred to as ddNTP. Additional examples of terminator compounds include 2'-PO₄ analogs of a ribonucleotide. Other unconventional nucleotides include phosphorothioate dNTP ([α]-S)dNTP, 5'-[α]-borano-dNTP, [α]-methyl-phosphonate dNTP, and ribonucleoside triphosphate (rNTP). An unconventional base may be labeled with a radioactive isotope, such as ³²P, ³³P, or ³⁵S; a fluorescent marker; a chemoluminescent marker; a bioluminescent marker; a hapten marker such as biotin; or an enzyme marker such as streptavidin or avidin. A fluorescent marker may be a negatively-charged dye such as a fluorescein-family dye, or a neutrally-charged dye such as a rhodamine-family dye, or a positively-charged dye such as a cyanine-family dye. Fluorescein-family dyes include, for example, FAM, HEX, TET, JOE, NAN and ZOE. Rhodamine-family dyes include Texas Red, ROX, R110, R6G, and TAMRA. Various dyes or nucleotides labeled with FAM, HEX, TET, JOE, NAN, ZOE, ROX, R110, R6G, Texas Red and TAMRA are commercially available from Perkin-Elmer (Boston, MA), Applied Biosystems (Foster City, CA), or Invitrogen/Molecular Probes (Eugene, OR). Cyanine-family dyes include Cy2, Cy3, Cy5 and Cy7, and are commercially available from GE Healthcare UK Limited (Amersham Place, Little Chalfont, Buckinghamshire, England).

[0072] The term "mismatch discrimination" refers to the ability of a biocatalyst (e.g., an enzyme such as a polymerase, ligase, or the like) to discriminate a fully-complementary sequence from a mismatch-containing sequence when a nucleic acid (e.g., primer or a different oligonucleotide) is extended by attaching (for example, covalently) one or more nucleotides to the nucleic acid in a template-dependent manner. The term "mismatch discrimination" refers to the ability of a biocatalyst to discriminate a fully-complementary sequence from a mismatch-containing (approximately complementary) sequence, that is, an extended nucleic acid (e.g., a primer or different oligonucleotide) has a mismatch in the 3'-end nucleic acid, compared with a nucleic acid-hybridized template. In some exemplary embodiments, an extended nucleic acid includes a mismatch at the 3' end with respect to a fully-complementary sequence. In some exemplary embodiments, an extended nucleic acid includes a mismatch at the penultimate (N-1) 3' position and/or at the N-2 position relative to the fully complementary sequence.

[0073] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as generally understood by those of ordinary skill in the art.

[0074] The present invention relates to a DNA polymerase comprising a Taq polymerase amino acid sequence of SEQ ID NO: 1, the DNA polymerase including

- (a) a substitution at amino acid residue 507 in the amino acid sequence of SEQ ID NO: 1;
- (b)

- (i) a substitution at amino acid residue 536 in the amino acid sequence of SEQ ID NO: 1,
- (ii) a substitution at amino acid residue 660 in the amino acid sequence of SEQ ID NO: 1,
- (iii) substitutions at amino acid residues 536 and 660 in the amino acid sequence of SEQ ID NO: 1, or
- (iv) substitutions at amino acid residues 536, 587 and 660 in the amino acid sequence of SEQ ID NO: 1.

[0075] The "Taq polymerase" is a heat-resistant DNA polymerase named after thermophilic bacteria *Thermus aquaticus*, and was first isolated from the bacteria. *Thermus aquaticus* are bacteria living in hot springs and hydrothermal vents, and the Taq polymerase is an enzyme that can tolerate a protein-denaturing condition (high temperature) required during PCR. The Taq polymerase has an optimal activity temperature of 75 to 80 °C, has a half-life of 2 hours or more at 92.5 °C, 40 minutes at 95 °C and 9 minutes at 97.5 °C, and can replicate 1000-bp DNA within 10 seconds at 72 °C. It lacks 3' → 5' exonuclease proofreading activity, resulting in an error rate of approximately 1 in 9,000 nucleotides. For example, when heat-resistant *Taq* is used, PCR may be performed at a high temperature (60 °C or more). The amino acid sequence set forth in SEQ ID NO: 1 is used as a reference sequence for the Taq polymerase.

[0076] According to an exemplary embodiment of the present invention, the substitution at amino acid residue 507 is a substitution of glutamic acid (E) with lysine (K), the substitution at amino acid residue 536 is a substitution of arginine (R) with lysine (K), the substitution at amino acid residue 587 is a substitution of arginine (R) with isoleucine (I), and the substitution at amino acid residue 660 may be a substitution of arginine (R) with valine (V).

[0077] In the present invention, the Taq polymerase in which glutamic acid (E) is substituted with lysine (K) at the amino acid residue 507 in the amino acid sequence of SEQ ID NO: 1 is named "E507K" (SEQ ID NO: 2); the Taq polymerase in which glutamic acid (E) is substituted with lysine (K) at the amino acid residue 507, and arginine (R) is substituted with lysine (K) at the amino acid residue 536 in the amino acid sequence of SEQ ID NO: 1 is named "E507K/R536K" (SEQ ID NO: 6); the Taq polymerase in which glutamic acid (E) is substituted with lysine (K) at the amino acid residue 507, and arginine (R) is substituted with valine (V) at the amino acid residue 660 in the amino acid sequence of SEQ ID NO: 1 is named "E507K/R660V" (SEQ ID NO: 7); the Taq polymerase in which glutamic acid (E)

is substituted with lysine (K) at the amino acid residue 507, arginine (R) is substituted with lysine (K) at the amino acid residue 536, and arginine (R) is substituted with valine (V) at the amino acid residue 660 in the amino acid sequence of SEQ ID NO: 1 is named "E507K/R536K/R660V" (SEQ ID NO: 8); and finally the Taq polymerase in which glutamic acid (E) is substituted with lysine (K) at the amino acid residue 507, arginine (R) is substituted with lysine (K) at the amino acid residue 536, arginine (R) is substituted with isoleucine (I) at the amino acid residue 587, and arginine (R) is substituted with valine (V) at the amino acid residue 660 in the amino acid sequence of SEQ ID NO: 1 is named "E507K/R536K/R587I/R660V" (SEQ ID NO: 37).

[0078] According to an exemplary embodiment of the present invention, the DNA polymerase discriminates a matched primer from a mismatched primer, the matched primer and the mismatched primer are hybridized with a target sequence, and the mismatched primer may include a non-canonical nucleotide at the 3' end with respect to a hybridized target sequence.

[0079] The mismatched primer is a hybrid oligonucleotide which should be sufficiently complementary to be hybridized with the target sequence, but does not correspond to the exact sequence of the target sequence.

[0080] The "canonical nucleotide" or "complementary nucleotide" means a standard Watson-Crick base pair, A-U, A-T or G-C.

[0081] The "non-canonical nucleotide" or "non-complementary nucleotide" means A-C, A-G, G-U, G-T, T-C, T-U, A-A, G-G, T-T, U-U, C-C, or C-U other than the Watson-Crick base pairs.

[0082] According to an exemplary embodiment of the present invention, with the DNA polymerase, the amplification of a target sequence including a matched primer may exhibit a lower Ct value than the amplification of a target sequence including a mismatched primer.

[0083] For example, the DNA polymerase may allow one or more nucleotides to covalently bind to a primer, thereby extending a matched primer with greater efficiency than a mismatched primer in a target sequence-dependent manner. Here, greater efficiency may be observed at a lower Ct value for a matched primer, compared with the mismatched primer, for example, in RT-PCR. The difference in Ct value between the matched primer and the mismatched primer may be 10 or more, and preferably, 10 to 20, or there may be no synthesis of an amplicon by a mismatched primer.

[0084] For example, such a difference means that a product formed by standard PCR using a forward primer and a reverse primer, which are matched in a first reaction, and a reverse primer matched with a mismatched forward primer in a second reaction with the same experiment settings is larger in the first reaction than in the second reaction.

[0085] A Ct (threshold crossing cycle) value represents a DNA quantification method by quantitative PCR, which depends on plotting the fluorescence representing the number of cycles on a log scale. The threshold for DNA-based fluorescence detection is set slightly higher than the minimum background. The number of cycles required for fluorescence to cross the threshold is called Ct or a quantification cycle (Cq) following the MIQE guidelines. The Ct value for the given reaction is defined as the number of cycles required for fluorescence emission to cross a fixed threshold. For example, SYBR Green I and a fluorescent probe may be used in real-time PCR for template DNA quantification. Fluorescence emitted from a sample is collected every cycle during PCR, and plotted against the number of cycles. A starting template concentration is inversely proportional to the time at which the fluorescent signal is first shown. The signal appears earlier as a template concentration is higher (shown at a low number of cycles).

[0086] The present invention also relates to a nucleic acid sequence encoding the above-described DNA polymerase, and a vector and a host cell, which include the nucleic acid sequence. Various vectors may be prepared using the nucleic acid encoding the DNA polymerase of the present invention. Any vector having a replicon and a control sequence, which are derived from a species compatible with a host cell, may be used. The vector of the present invention may be an expression vector, and has nucleic acid regions for regulating transcription and translation, which are operably linked to the nucleic acid sequence encoding the DNA polymerase of the present invention. The regulatory sequence refers to a DNA sequence required for the expression of a coding sequence operably linked to a specific host organism. For example, a control sequence suitable for a prokaryote includes a promoter, any operating sequence and a ribosome binding sequence. In addition, a vector may include a "positive retroregulatory element (PRE)" to increase the half-life of mRNA to be transcribed. Transcription and translation regulatory nucleic acid regions may be generally suitable for host cells used to express a polymerase. Various types of suitable expression vectors and regulatory sequences are known to be used for various host cells. Generally, transcription and translation regulatory sequences may include, for example, a promoter sequence, a ribosome binding site, transcription initiation and termination sequences, translation initiation and termination sequences, and an enhancer or activation sequence. In a typical, exemplary embodiment, regulatory sequences include a promoter and transcription initiation and termination sequences. Typically, a vector also includes a polylinker region containing several restriction sites for inserting foreign DNA. In a specific exemplary embodiment, the "fusion flag" is used to promote purification, and if necessary, a tag/flag is subsequently removed (e.g., "His-Tag"). However, when thermoactive and/or thermostable protein(s) is(are) purified from mesophilic hosts (e.g., *E. coli*) using a "heating step," the fusion flags are generally unnecessary. A suitable vector containing a DNA encoding replication sequence, a regulatory sequence and a phenotype selection gene is constructed, and a mutant polymerase of interest is prepared using a standard recombinant DNA technique. An isolated plasmid, a viral vector and a DNA

fragment are digested and cleaved, and then ligated with each other in a specific order to form a desired vector as known in the art.

[0087] In an exemplary embodiment of the present invention, an expression vector contains a selectable marker gene to select a transformed host cell. Selection genes are known in the art, and may vary according to the host cells used herein. Suitable selection genes may include the gene coding for ampicillin and/or tetracycline resistance, and may allow cells in which these vectors are cultured in the presence of these antibiotics to be transformed.

[0088] In an exemplary embodiment of the present invention, a nucleic acid sequence encoding the DNA polymerase of the present invention may be introduced into cells alone or in combination with a vector. The introduction or equivalent expressions thereof refer to a nucleic acid entering cells in the method suitable for subsequent integration, amplification and/or expression. The introduction method includes, for example, CaPO₄ precipitation, liposome fusion, LIPOFECTIN®, electrophoresis, and viral infection.

[0089] Prokaryotes are used as host cells in an early cloning step of the present invention. They are particularly useful for rapidly preparing a great quantity of DNA, for preparing a single-stranded DNA template used in site-directed mutagenesis, for simultaneously screening many mutants, and for DNA sequencing of generated mutants. Suitable prokaryotic host cells include *E. coli* K12 strain 94 (ATCC No. 31,446), *E. coli* strain W3110 (ATCC No. 27,325), *E. coli* K12 strain DG116 (ATCC No. 53,606), *E. coli* X1776 (ATCC No. 31,537), and *E. coli* B; many other strains of *E. coli*, such as HB101, JM101, NM522, NM538 and NM539, and other species such as Bacilli, e.g., *Bacillus subtilis*, other Enterobacteriaceae, e.g., *Salmonella typhimurium* or *Serratia marcescens*, and prokaryotic genera including various *Pseudomonas* sp. may be used as hosts. Typically, plasmids used in the transformation of *E. coli* include pBR322, pUC18, pUC19, pUC118, pUC119 and Bluescript M13. However, many other suitable vectors may also be used.

[0090] The present invention also provides a method of preparing a DNA polymerase, which includes: culturing the host cells; and isolating a DNA polymerase from a cell culture and a supernatant thereof.

[0091] The DNA polymerase of the present invention is prepared by culturing host cells transformed with an expression vector containing a nucleic acid sequence encoding the DNA polymerase under suitable conditions inducing or causing the expression of the DNA polymerase. A method of culturing the transformed host cells under conditions suitable for protein expression is known in the art. Host cells suitable for the preparation of a polymerase from a lambda (λ) pL promoter-containing plasmid vector include *E. coli* strain DG116 (ATCC No. 53606). When expressed, the polymerase may be collected and isolated.

[0092] After purification, mismatch discrimination of the DNA polymerase of the present invention may be assayed. For example, mismatch discrimination activity is measured by comparing the amplification of a target sequence perfectly matched with a primer with respect to the amplification of a target having a single base mismatch at the 3' end of a primer. The amplification may be detected in real time by using, for example, a TaqMan™ probe. The ability of a polymerase to distinguish between two target sequences may be assumed by comparing Cts in two reactions.

[0093] Therefore, the present invention provides a method of *in vitro* detecting one or more gene variations or SNPs in one or more templates, the method including: bringing the DNA polymerase according to the present invention into contact with

a) one or more templates,

b) a nucleoside triphosphate, and

c) one or more matched primers, one or more mismatched primers or both of one or more matched primers and one or more mismatched primers, wherein the one or more matched primers and the one or more mismatched primers are hybridized with a target sequence, and the mismatched primer has a non-canonical nucleotide at base position 7 from the 3' end thereof with respect to the hybridized target sequence.

[0094] The "single-nucleotide polymorphism (SNP)" refers to a genetic change or variation showing the difference of a single base (A, T, G or C) in a DNA base sequence.

[0095] In the method of *in vitro* detecting a gene variation or SNP, a target sequence may be present in a test sample, including, for example, DNA, cDNA or RNA, and preferably, genomic DNA. The test sample may be a cell lysate prepared from bacteria, a bacterial culture, or a cell culture. In addition, the test sample may be one included in an animal, preferably, a vertebrate, and more preferably, a human subject. The target sequence may be genomic DNA, preferably, genomic DNA of an individual, more preferably, bacteria or a vertebrate, and most preferably, genomic DNA of a human subject.

[0096] The SNP detection method of the present invention may include analysis of a melting temperature using a double strand-specific dye such as SYBR Green I.

[0097] The analysis of a melting temperature curve may be performed in a real-time PCR instrument such as ABI 5700/7000 (96-well format) or ABI 7900 (384-well format) instrument with onboard software (SDS 2.1). Alternatively, the analysis of a melting temperature curve may be performed as end-point analysis.

[0098] The "dye binding to double-stranded DNA" or "double strand-specific dye" may be used when high fluorescence

is emitted while binding to double-stranded DNA, rather than in an unbound state. Examples of these dyes are SOYTO-9, SOYTO-13, SOYTO-16, SOYTO-60, SOYTO-64, SYTO-82, ethidium bromide (EtBr), SYTOX Orange, TO-PRO-1, SYBR Green I, TO-PRO-3 or EvaGreen. These dyes excluding EtBr and EvaGreen (Qiagen) have been tested in real-time applications.

[0099] The method of *in vitro* detecting a gene variation or SNP may be performed by real-time PCR, analysis on agarose gel after standard PCR, gene variation-specific amplification or allele-specific amplification through real-time PCR, tetra-primer amplification-refractory mutation system PCR or isothermal amplification, but the present invention is not limited thereto.

[0100] For example, the SNP detection method of the present invention may be performed using sequencing, mini-sequencing, allele-specific PCR, dynamic allele-specific hybridization (DASH), a PCR extension assay (e.g., single base extension; SBE), PCR-SSCP, a PCR-RFLP assay or TaqMan method, SNPlex platform (Applied Biosystems), mass spectrometry (e.g., MassARRAY system of Sequenom), or a Bio-Plex system (BioRad).

[0101] The "standard PCR" is a technique for amplifying single or several copies of DNA or cDNA known to a technician of ordinary skill in the art. Almost all PCR techniques use a thermostable DNA polymerase such as Taq polymerase or Klen Taq. A DNA polymerase uses single-stranded DNA as a template, and enzymatically assembles a new DNA strand from nucleotides using oligonucleotide primers. Amplicons generated by PCR may be analyzed on, for example, agarose gel.

[0102] The "real-time PCR" may monitor a PCR process in real time. Therefore, data is collected throughout the PCR process, not at the end of PCR. In the real-time PCR, the reaction is characterized by the point of time during a cycle when amplification is first detected, rather than the amount of a target accumulated after a fixed number of cycles. Usually, both of dye-based detection and probe-based detection are used to perform quantitative PCR.

[0103] The "allele-specific amplification (ASA)" is an amplification technique for designing PCR primers to discriminate templates with different single nucleotide residues.

[0104] The "allele-specific amplification or gene variation-specific amplification through real-time PCR" is a highly effective method for detecting a gene variation or SNP. Unlike most of other methods for detecting a gene variation or SNP, the pre-amplification of a target gene material is not needed. ASA combines amplification and detection in a single reaction based on the discrimination between matched and mismatched primer/target sequence complex. The increase in amplified DNA during the reaction may be monitored in real time with the increase in fluorescent signal caused by a dye such as SYBR Green I emitted upon binding to double-stranded DNA. The allele-specific amplification or gene variation-specific amplification through real-time PCR shows the delay or absence of a fluorescent signal when a primer is mismatched. In the gene variation or SNP detection, such amplification provides information on the presence or absence of a gene variation or SNP.

[0105] The "tetra-primer amplification-refractory mutation system PCR" is amplification of all of wild-type and mutant alleles with a control fragment in single tube PCR. A non-allele-specific control amplicon is amplified by two common (outside) primers flanking a mutation region. The two allele-specific (inside) primers are designed in an opposite direction to the common primers, both of wild-type and mutant amplicons may be simultaneously amplified with the common primers. As a result, two allele-specific amplicons may have different lengths since mutations are asymmetrically located based on the common (outside) primers, and easily separated by standard gel electrophoresis. The control amplicons provide an internal control for false negative results as well as amplification failure, and at least one of the two allele-specific amplicons is always present in the tetra-primer amplification-refractory mutation system PCR.

[0106] The "isothermal amplification" means that the amplification of a nucleic acid is not dependent on a thermocycler and is performed at a lower temperature without the need for temperature change during amplification. The temperature used in isothermal amplification may range from room temperature (22 to 24 °C) to approximately 65 °C, or approximately 60 to 65 °C, 45 to 50 °C, 37 to 42 °C or room temperature (22 to 24 °C). A product obtained by the isothermal amplification may be detected by gel electrophoresis, ELISA, enzyme-linked oligosorbent assay (ELOSA), real-time PCR, enhanced chemiluminescence (ECL), a chip-based capillary electrophoresis device, such as a bioanalyzer, for analyzing RNA, DNA and protein or turbidity.

[0107] In an exemplary embodiment of the present invention, E507K/R536K, E507K/R660V, or E507K/R536K/R660V Taq polymerase was used to confirm whether an ability of extending a mismatched primer with respect to a template including a SNP (rs1408799, rs1015362 and/or rs4911414) was reduced.

[0108] As a result, as shown in FIGS. 6a-6d, 7 and 8, compared to E507K Taq polymerase, in the case of the E507K/R536K, E507K/R660V or E507K/R536K/R660V Taq polymerase, it can be confirmed that amplification with a mismatched primer is delayed, and such an effect was most clearly shown in the case of the E507K/R536K/R660V Taq polymerase.

[0109] To this end, it was confirmed that the three types of DNA polymerases have higher mismatch extension selectivity than the conventional Taq polymerase (E507K). Therefore, it is expected that the DNA polymerase of the present invention can be effectively used in medical diagnosis of a disease and recombinant DNA studies.

[0110] In another exemplary embodiment of the present invention, the E507K/R536K/R660V Taq polymerase was

used to confirm whether an ability of extending mismatched primers with respect to a template with Q61H, G13D or G12S SNP at the KRAS gene, and a template with L858R SNP at the EGFR gene was reduced.

[0111] As a result, as shown in FIGS. 10a to 10d, 11, 12 and 13, it was confirmed that Taq DNA polymerase having E507K/R536K/R587I/R660V variations, compared with Taq polymerase having E507K/R536K/R660V variations, has superior mismatch extension selectivity. Therefore, it is expected that the Taq DNA polymerase having E507K/R536K/R587I/R660V variations according to the present invention can also be effectively used in medical diagnosis of a disease and recombinant DNA studies.

[0112] The present invention also relates to a composition for detecting a gene variation or SNP, which includes the DNA polymerase according to the present invention, and a PCR kit including the same.

[0113] According to an exemplary embodiment of the present invention, the PCR kit may be applied to general PCR (first generation PCR), real-time PCR (second generation PCR), digital PCR (third generation PCR) or MassARRAY.

[0114] In the PCR kit of the present invention, the digital PCR may be competitive allele-specific TaqMan PCR (CAST PCR) or droplet digital PCR (ddPCR), and more specifically, allele-specific cast PCR or allele-specific droplet digital PCR, but the present invention is not limited thereto.

[0115] The "CAST PCR" is a method of detecting and quantifying rare mutations from a large amount of sample containing normal wild-type gDNA, and to inhibit non-specific amplification from a wild-type allele, higher specificity may be generated by the combination of allele-specific TaqMan® qPCR with an allele-specific MGB inhibitor, compared to traditional allele-specific PCR.

[0116] The "droplet digital PCR" is a system for counting target DNA after a 20 μ l PCR product is fractionated into 20,000 droplets and then amplified, and may be used to count positive droplets (1) and negative droplets (0) considered as digital signals according to the amplification of target DNA in droplets, calculate the number of copies of target DNA by the Poisson distribution, and finally determine result values with the number of copies per μ l sample, and used to detect rare mutations, amplify a very small amount of gene and simultaneously confirm a mutation type.

[0117] The "MassARRAY" is a multiplexing analysis method that can be applied to various genome studies such as genotyping, using a MALDI-TOF mass spectrometer, and may be used to rapidly analyze various samples and targets at low cost or to perform customized analysis only for a specific target.

[0118] The PCR kit of the present invention may include any reagent or other elements, which are recognized for use in primer extension by technicians of ordinary skill in the art.

[0119] According to an exemplary embodiment of the present invention, the PCR kit may further include one or more matched primers, one or more mismatched primers or both of one or more matched primers and one or more mismatched primers, wherein the one or more matched primers and one or more mismatched primers are hybridized with a target sequence, and the mismatched primer may include a non-canonical nucleotide at a position of 7 bases from the 3' end of the primer with respect to the hybridized target sequence.

[0120] The PCR kit of the present invention may further include a nucleoside triphosphate.

[0121] The PCR kit of the present invention may further include a) one or more buffers; b) a quantification reagent binding to double-stranded DNA; c) a polymerase blocking antibody; d) one or more control values or control sequences; and e) one or more templates.

[0122] The present invention relates to a PCR buffer composition for increasing the activity of a DNA polymerase with increased gene variation specificity, which includes 25 to 100 mM KCl; and 1 to 15 mM $(\text{NH}_4)_2\text{SO}_4$, and has the final pH of 8.0 to 9.0.

[0123] Polymerases used in PCR should be optimal reaction buffers mixed with various materials to perform proper functions. The reaction buffers generally contain an element for pH stabilization, a metal ion as a cofactor, and a stabilization element for preventing the denaturation of a polymerase.

[0124] The KCl is an element required for enzyme stabilization, and helps pairing of a primer to target DNA. In the present invention, an optimal concentration was determined by adjusting a KCl concentration in the reaction buffer to confirm a cation concentration in a state in which the amplification by mismatching is delayed as much as possible, and the amplification efficiency by matching is not reduced.

[0125] As a result of confirming an amplification delay effect by mismatching according to the change in KCl concentration in the reaction buffer using each of E507K, E507K/R536K, E507K/R660V and E507K/R536K/R660V Taq polymerases, as shown in FIGS. 14a to 14d, the E507K/R536K/R660V Taq polymerase showed an excellent amplification delay effect caused by mismatching without KCl in the reaction buffer, the E507K/R536K and E507K/R660V Taq polymerases showed an excellent amplification delay effect caused by mismatching at 50 mM, and the control E507KTaq polymerase showed an excellent amplification delay effect caused by mismatching at 100 mM. Consequently, it was confirmed that the KCl concentration threshold is the lowest for the E507K/R536K/R660V Taq polymerase, and lower for the E507K/R536K and E507K/R660V Taq polymerases, compared to that of E507K Taq polymerase.

[0126] In addition, to determine the optimal KCl concentration, the E507K/R536K/R660V Taq polymerase was used, and amplification was performed by variously changing a KCl concentration while a $(\text{NH}_4)_2\text{SO}_4$ concentration was constantly fixed in the reaction buffer. As a result of electrophoresis performed on an amplicon, as shown in FIG. 15,

the optimal KCl concentration was confirmed to be 75 mM.

[0127] Therefore, the KCl concentration of the PCR buffer composition of the present invention may be 25 to 100 mM, preferably, 60 to 90 mM, more preferably, 70 to 80 mM, and most preferably, 75 mM

[0128] When the KCl concentration is less than 25 mM, it has no influence on general target amplification, but a difference between amplification by a matched primer and amplification by a mismatched primer may be reduced, and when the KCl concentration is more than 100 mM, the efficiency of general target amplification may be lowered.

[0129] In the PCR buffer composition, the $(\text{NH}_4)_2\text{SO}_4$ is a cofactor required for enzyme activity, and used to increase polymerase activity along with Tris. In an exemplary embodiment of the present invention, based on the determined results, the KCl concentration in the reaction buffer was constantly fixed at 75mM, and the $(\text{NH}_4)_2\text{SO}_4$ concentration varied from 2.5 mM to 25 mM, so that the optimal $(\text{NH}_4)_2\text{SO}_4$ concentration was confirmed.

[0130] As a result, as shown in FIG. 16, at the $(\text{NH}_4)_2\text{SO}_4$ concentrations ranging from 2.5 to 15 mM, an amplicon was identified, confirming that the optimal $(\text{NH}_4)_2\text{SO}_4$ concentration was 5 mM.

[0131] In addition, by performing AS-qPCR at $(\text{NH}_4)_2\text{SO}_4$ concentrations of approximately 5 mM (2.5 mM, 5 mM and 10 mM), as shown in FIG. 17, it was confirmed that the Ct difference was the highest at 10 mM, but Ct was a little delayed and a peak was tilted in the amplification caused by matching, and the optimal $(\text{NH}_4)_2\text{SO}_4$ concentration was determined to be 5 mM.

[0132] Therefore, the $(\text{NH}_4)_2\text{SO}_4$ concentration in the PCR buffer composition may be 1 to 15 mM, preferably, 2.5 to 8 mM, more preferably, 4 to 6 mM, and most preferably, 5 mM.

[0133] When the $(\text{NH}_4)_2\text{SO}_4$ concentration is less than 1 mM, there was no influence on general target amplification, but the difference between the amplification by a matched primer and the amplification by a mismatched primer may be reduced, and when the $(\text{NH}_4)_2\text{SO}_4$ concentration is more than 15 mM, the general target amplification efficiency may be lowered.

[0134] Therefore, the optimized PCR buffer composition of the present invention may contain 70 to 80 mM KCl and 4 to 6 mM $(\text{NH}_4)_2\text{SO}_4$, and the final pH is 8.0 to 9.0.

[0135] The PCR buffer composition of the present invention may further include 5 to 80 mM tetra methyl ammonium chloride (TMAC).

[0136] TMAC is generally used to reduce amplification caused by mismatching or improve the stringency of a hybridization reaction. In an exemplary embodiment of the present invention, based on the obtained results, the optimal TMAC concentration was determined by fixing the KCl concentration at 75 mM, and the $(\text{NH}_4)_2\text{SO}_4$ concentration at 5 mM in the reaction buffer, and varying a TMAC concentration from 0 to 80 mM

[0137] As a result, as shown in FIGS. 18a and 18b, it was confirmed that the optimal TMC concentration was 70 mM for the E507K/R536K Taq polymerase, and 25 mM for the E507K/R536K/R660V Taq polymerase. In addition, as a result of amplification performed by constantly fixing a TMAC concentration at 25 mM and a $(\text{NH}_4)_2\text{SO}_4$ concentration at 2.5 mM, and varying a KCl concentration to 20, 40, 60 and 80 mM, as shown in FIGS. 19a and 19b, the optimal KCl concentration for SNP rs1015362 and rs4911414 was determined to be 60 mM.

[0138] When the TMAC concentration is more than 80 mM, amplification efficiency is reduced, and thus it is preferable that the TMAC concentration is in the above-mentioned range.

[0139] Therefore, when the PCR buffer composition of the present invention contains 5 to 80 mM TMAC, the KCl concentration may be 40 to 90 mM, and preferably, 50 to 80 mM, and the $(\text{NH}_4)_2\text{SO}_4$ concentration may be 1 to 7 mM, and preferably 1.5 to 6 mM.

[0140] When TMAC is contained, the optimized PCR buffer composition of the present invention may contain 15 to 70 mM TMAC, 50 to 80 mM KCl, and 1.5 to 6 mM $(\text{NH}_4)_2\text{SO}_4$, and the final pH may be 8.0 to 9.0.

[0141] The PCR buffer composition of the present invention may further contain Tris Cl and MgCl_2 , and additionally contain Tween 20 and bovine serum albumin (BSA).

[0142] The present invention also provides a PCR kit for detecting a gene variation or SNP, which includes the above-described PCR buffer composition.

[0143] The PCR kit of the present invention may further include a DNA polymerase comprising a Taq polymerase amino acid sequence of SEQ ID NO: 1, where the DNA polymerase has substitution(s) of the following amino acids:

- (a) a substitution at amino acid residue 507 in the amino acid sequence of SEQ ID NO: 1; and
- (b)

- (i) a substitution at amino acid residue 536 in the amino acid sequence of SEQ ID NO: 1,
- (ii) a substitution at amino acid residue 660 in the amino acid sequence of SEQ ID NO: 1,
- (iii) substitutions at amino acid residues 536 and 660 in the amino acid sequence of SEQ ID NO: 1, or
- (iv) substitutions at amino acid residues 536, 587 and 660 in the amino acid sequence of SEQ ID NO: 1.

[0144] According to an exemplary embodiment of the present invention, the substitution at the amino acid residue 507

may be a substitution of glutamic acid (E) with lysine (K), the substitution at the amino acid residue 536 may be a substitution of arginine (R) with lysine (K), the substitution at the amino acid residue 587 may be a substitution of arginine (R) with isoleucine (I), and the substitution at the amino acid residue 660 may be a substitution of arginine (R) with valine (V).

[0145] An additional description of the DNA polymerase included in the PCR kit of the present invention is the same as described above, and therefore, the overlapping description will be omitted.

[0146] Other components of the PCR kit for detecting a gene variation or SNP, which includes the PCR buffer composition of the present invention are the same as described above, and the overlapping description will be omitted.

[0147] The present invention also relates to a method of *in vitro* detecting one or more gene variations or SNPs using the kit for detecting a gene variation or SNP, which includes the PCR buffer composition for increasing activity of the DNA polymerase with increased gene variation specificity.

[0148] The method is the same as the method of *in vitro* detecting one or more gene variations or SNPs in one or more templates using the DNA polymerase with increased gene variation specificity of the present invention, except the components of the PCR buffer composition, and therefore, the overlapping description will be omitted.

[0149] Hereinafter, the present invention will be described in further detail with reference to examples. The examples are merely provided to more fully describe the present invention, and it will be obvious to those of ordinary skill in the art that the scope of the present invention is not limited to the following examples.

[Examples]

[Example 1]

Mutagenesis of Taq polymerase

1-1. Fragment PCR

[0150] In this example, Taq DNA polymerase in which arginine was substituted with lysine at amino acid residue 536 in the amino acid sequence of SEQ ID NO: 1 (hereinafter, referred to as "R536K"), Taq DNA polymerase in which arginine was substituted with valine at amino acid residue 660 in the amino acid sequence of SEQ ID NO: 1 (hereinafter, referred to as "R660V") and Taq DNA polymerase in which arginine was substituted with lysine at amino acid residue 536 and arginine was substituted with valine at amino acid residue 660 in the amino acid sequence of SEQ ID NO: 1 (hereinafter, referred to as "R536K/R660V") were prepared as follows.

[0151] First, using mutation-specific primers described in Table 1, as shown in (a) in FIG. 1, Taq DNA polymerase fragments (F1 to F5) were amplified by PCR. Reaction conditions are as in Table 2.

[Table 1]

Primer	Sequence (5'→ 3')
Eco-F	GG GGTACC TCA TCA CCC CGG (SEQ ID NO: 17)
R536K-R	CTT GGT GAG CTC CTT GTA CTG CAG GAT (SEQ ID NO: 18)
R536K-F	ATC CTG CAG TAC AAG GAG CTC ACC AAG (SEQ ID NO: 19)
R660V-R	GAT GGT CTT GGC CGC CAC GCG CAT CAG GGG (SEQ ID NO: 20)
R660V-F	CCC CTG ATG CGC GTG GCG GCC AAG ACC ATC (SEQ ID NO: 21)
Xba-R	GC TCTAGA CTA TCA CTC CTT GGC GGA GAG CCA (SEQ ID NO: 22)

[Table 2]

10X pfu buffer (SolGent)	2.5 μ l
dNTP (10 mM each)	1 μ l
F primer (10 pmol/ μ l)	1 μ l
R primer (10 pmol/ μ l)	1 μ l
Distilled water	18 μ l

EP 3 653 729 A1

(continued)

pUC19-Ta _q (10 ng/μl)	1 μl
Pfu polymerase	0.5 μl
30 cycles (Ta=60°C)	25 μl

[0152] PCR products were subjected to electrophoresis, thereby detecting a band for each fragment as shown in (b) in FIG. 1, indicating that a desired fragment was amplified.

1-2. Overlap PCR

[0153] Each amplified fragment obtained in 1-1 was used as a template, and full-length amplification thereof was performed using primers at both ends (Eco-F and Xba-R primers). Reaction conditions are as in Tables 3 and 4.

[Table 3]

R660V or R536K	
10X pfu buffer (SolGent)	5 μl
5X enhancer (SolGent)	10 μl
dNTP (10 mM each)	1 μl
Eco-F primer (10 pmol/μl)	2 μl
Xba-R primer (10 pmol/μl)	2 μl
Distilled water	27 μl
Fragment 1 (or fragment 3)	1 μl
Fragment 2 (or fragment 4)	1 μl
Pfu polymerase	1 μl
40 cycles (Ta=62°C)	50 μl

[Table 4]

R536K/R660V	
10X pfu buffer (SolGent)	5 μl
5X enhancer (SolGent)	10 μl
dNTP (10 mM each)	1 μl
Eco-F primer (10 pmol/μl)	2 μl
Xba-R primer (10 pmol/μl)	2 μl
Distilled water	26 μl
Fragment 2	1 μl
Fragment 3	1 μl
Fragment 5	1 μl
Pfu polymerase	1 μl
40 cycles (Ta=62°C)	50 μl

[0154] Consequently, as shown in (c) in FIG. 1, it was confirmed that the Ta_q polymerases of "R536K," "R660V" and "R536K/R660V" were amplified.

EP 3 653 729 A1

1-3. Ligation

[0155] pUC19 was digested with restriction enzymes EcoRI/XbaI at 37 °C for 4 hours under conditions shown in Table 5 below, DNA was purified, and the purified DNA was treated with SAP at 37 °C for 1 hour under conditions shown in Table 6, thereby preparing a vector.

[Table 5]

10X CutSmart buffer (NEB)	2.5 µl
pUC19 (500 ng/µl)	21.5 µl
EcoRI-HF (NEB)	0.5 µl
Xba I (NEB)	0.5 µl
25 µl	

[Table 6]

10X SAP buffer (Roche)	2 µl
Purified DNA	17 µl
SAP (Roche)	1 µl
20 µl	

[0156] After the overlap PCR product was obtained in Example 1-2 and digested with restriction enzymes EcoRI/XbaI at 37 °C for 3 hours under conditions shown in Table 7, an insert was gel-extracted with the prepared vector (FIG. 2).

[Table 7]

10X CutSmart buffer (NEB)	2 µl
Purified PCR product	17 µl
EcoRI-HF (NEB)	0.5 µl
XbaI (NEB)	0.5 µl
20 µl	

[0157] After ligation was performed at room temperature for 2 hours under conditions shown in Table 8, *E. coli* DH5α was transformed with the resulting vectors and then screened in a medium containing ampicillin. Plasmids prepared from the collected colonies were sequenced, thereby obtaining Taq DNA polymerase mutants ("R536K," "R660V" and "R536K/R660V") into which desired variation(s) is/are introduced.

[Table 8]

	Vector only	Vector+Insert
10X ligase buffer (SolGent)	1 µl	1 µl
Vector	1 µl	1 µl
Insert	-	3 µl
Distilled water	7 µl	4 µl
T4 DNA ligase (SolGent)	1 µl	1 µl
	10 µl	10 µl

[Example 2]

Introduction of E507K variation

2-1. Fragment PCR

[0158] The Taq polymerase activity of the "R536K," "R660V" and "R536K/R660V" prepared in Example 1 was tested, thereby confirming that the activity was decreased (data not shown), the E507K variation (substitution of glutamic acid with lysine at amino acid residue 507 in the amino acid sequence of SEQ ID NO: 1) was additionally introduced into each of R536K, R660V and R536K/R660V, and the E507K variation was introduced into wild-type Taq DNA polymerase (WT) as a control. A method of preparing the E507K variation-introduced Taq DNA polymerase is the same as described in Example 1.

[0159] Taq DNA polymerase fragments (F6 to F7) shown in Table 3 were amplified by PCR using mutation-specific primers shown in Table 9. Reaction conditions are shown in Table 10.

[Table 9]

Primer	Sequence (5'-3')
Eco-F	GG GGTACC TCA TCA CCC CGG (SEQ ID NO: 17)
E507K-R	CTT GCC GGT CTT TTT CGT CTT GCC GAT (SEQ ID NO: 23)
E507K-F	ATC GGC AAG ACG AAA AAG ACC GGC AAG (SEQ ID NO: 24)
Xba-R	GC TCTAGA CTA TCA CTC CTT GGC GGA GAG CCA (SEQ ID NO: 22)

[Table 10]

10X pfu buffer (SolGent)	2.5 μ l
dNTP (10 mM each)	1 μ l
F primer (10 pmol/ μ l)	1 μ l
R primer (10 pmol/ μ l)	1 μ l
Distilled water	18 μ l
Template plasmid (10 ng/ μ l)	1 μ l
Pfu polymerase	0.5 μ l
30 cycles (Ta=60 $^{\circ}$ C)	25 μ l
*Template plasmids: pUC19-Ta q (WT), pUC19-Ta q (R536K), pUC19-Ta q (R660V), and pUC19-Ta q (R536K/R660V)	

2-2. Overlap PCR

[0160] Full-length amplification was performed on each of the amplified fragments obtained in 2-1 as a template using primers (Eco-F and Xba-R primers) at both ends. Reaction conditions are shown in Table 11.

[Table 11]

10X pfu buffer (SolGent)	5 μ l
5X enhancer (SolGent)	10 μ l
dNTP (10 mM each)	1 μ l
Eco-F primer (10 pmol/ μ l)	2 μ l
Xba-R primer (10 pmol/ μ l)	2 μ l
Distilled water	27 μ l
Fragment 6	1 μ l

(continued)

Fragment 7	1 μ l
Pfu polymerase	1 μ l
40 cycles (Ta=62°C)	50 μ l

2-3. Ligation

[0161] pUC19 was digested with restriction enzymes EcoRI/XbaI at 37 °C for 4 hours under conditions shown in Table 5 above, DNA was purified, the purified DNA was treated with SAP at 37 °C for 1 hour under conditions shown in Table 6, thereby preparing a vector.

[0162] After the overlap PCR product was obtained in Example 2-2 and digested with restriction enzymes EcoRI/XbaI at 37 °C for 3 hours under conditions shown in Table 7, an insert was gel-extracted with the prepared vector (FIG. 4).

[0163] After ligation was performed at room temperature for 2 hours under conditions shown in Table 8, *E. coli* DH5 α or DH10 β was transformed with the resulting vectors and then screened in a medium containing ampicillin. Plasmids prepared from the collected colonies were sequenced, thereby obtaining E507K variation-introduced Taq DNA polymerase mutants ("E507K/R536K," "E507K/R660V" and "E507K/R536K/R660V").

[Example 3]

Performance of qPCR using DNA polymerase of the present invention

[0164] The Taq polymerase having each of the "E507K/R536K," "E507K/R660V" and "E507K/R536K/R660Y" variations obtained in Example 2 was used to confirm whether an ability of extending a mismatched primer with respect to a template including a SNP was reduced. As a control, the "E507K" Taq polymerase having the E507K variation was used.

[0165] The templates including SNPs used herein are rs1408799, rs1015362 and rs4911414, and genotypes of the templates and sequence data of specific primers (IDT, USA) thereof are shown in Tables 12 and 13 below.

[Table 12]

Genotype of template	
rs1408799	TT
rs1015362	CC
rs4911414	GG

[Table 13]

Primer Name		Sequence (5' - 3')
rs1408799	Forward	CCAGTGTTAGGTTATTTCTAACTTG (SEQ ID NO: 25)
	Reverse_T	GCTCGGAGCACATGGTCAA (SEQ ID NO: 26)
	Reverse_C	GCTCGGAGCACATGGTCAG (SEQ ID NO: 27)
rs1015362	Forward	TGAAGAGCAGGAAAGTTCTTCA (SEQ ID NO: 28)
	Reverse_C	ACTGTGTGTCTGAAACAGTG (SEQ ID NO: 29)
	Reverse_T	ACTGTGTGTCTGAAACAGTA (SEQ ID NO: 30)
rs4911414	Forward_G	GTAAGTCTTTGCTGAGAAATTCATTG (SEQ ID NO: 31)
	Forward_T	GTAAGTCTTTGCTGAGAAATTCATTT (SEQ ID NO: 32)
	Reverse	AGTATCCAGGGTTAATGTGAAAG (SEQ ID NO: 33)

[0166] Conditions for qPCR (Applied Biosystems 7500 Fast) are as shown in Table 14 below.

EP 3 653 729 A1

[Table 14]

95 □ 5 min	
95 □ 20 sec	50 cycles
60 □ 30 sec	
72 □ 30 sec	
72 □ 3 min	

[0167] Probes were dual-labeled as shown in Table 15 below.

[Table 15]

Probe Name	Sequence (5'-3')	5' fluorophore	3' quencher
1408799-FAM	AGATATTTGTAAGGTATTCTGGCCT (SEQ ID NO: 34)	FAM	Black Hole Quencher 1
1015362-HEX	TGCTGAACAAATAGTCCCGACCAG (SEQ ID NO: 35)	HEX	Black Hole Quencher 1
4911141-Texas Red	TTTCTCTAGTTGCCTTTAAGATTT (SEQ ID NO: 36)	Texas Red	Black Hole Quencher 2

[0168] Oral epithelial cells were collected using a kit for collecting oral epithelial cells purchased from Noble Bio, lysed in 500 μ l of a lysis solution, and then centrifuged at 12,000x g for 3 minutes. The supernatant was transferred to a fresh tube, and 1 μ l per experiment was used (FIG. 5). Reaction conditions are shown in Table 16, and the composition of the reaction buffer is shown in Table 17.

[Table 16]

5X reaction buffer	4 μ l
5M betaine	2 μ l
dNTP (10 mM each)	0.5 μ l
Forward primer (2 μ M)	1 μ l
Reverse primer (2 μ M)	1 μ l
Nuclease-free distilled water	8 μ l
Acquired template	1 μ l
Taq polymerase (2 U/ μ l)	0.5 μ l
Dual-labeled probe (4 μ M)	2 μ l
20 μ l	

[Table 17]

Reaction buffer (1X)
50 mM Tris·Cl (pH 8.8)
2.5 mM MgCl ₂
50 mM KCl
5 mM (NH ₄) ₂ SO ₄
0.1% Tween 20
0.01 %BSA

[0169] The other components of the reaction solution except a specific primer were prepared as shown in Table 13 in two tubes, and each allele-specific primer was added thereto, thereby performing qPCR. Here, a difference in cycle (Ct) value at which combined fluorescent signals detected from the tubes reach the threshold fluorescence value calculated with AB 7500 software (v2.0.6) was analyzed. It is considered that, as the Ct value in the amplification by a mismatched primer is delayed, high gene variation specificity or allele specificity is exhibited. As a result of AS-qPCR for rs1408799, rs1015362 and rs4911414, as shown in FIGS. 6a-6d, 7 and 8, compared to the control E507K, when the Taq polymerase having E507K/R536K, E507K/R660V or E507K/R536K/R660V variations was used, it was confirmed that the amplification by a mismatched primer was delayed, and such an effect was most significantly exhibited in the E507K/R536K/R660V mutant.

[0170] It was confirmed that the Taq DNA polymerase having the E507K/R536K, E507K/R660V or E507K/R536K/R660V variations according to the present invention, compared to that with E507K variation, has excellent mismatch extension selectivity. Therefore, it is expected that the three types of Taq DNA polymerases can be useful for medical diagnosis of a disease and recombinant DNA studies.

[Example 4]

Introduction of R587I variation

4-1. Fragment PCR

[0171] To additionally introduce a R587I variation (substitution of arginine with isoleucine at amino acid residue 587 in the amino acid sequence of SEQ ID NO: 1) into the "E507K/R536K/R660V" variation-introduced Taq clone prepared in Example 2, as shown in (a) in FIG. 9, two fragments were amplified by PCR using primers shown in Table 18 below. Reaction conditions are shown in Table 19.

[Table 18]

Primer	Sequence (5'-3')
Kpn-F	TCC ACC CCG AGG GGT ACC TCA TCA CCC CGG CCT GGC (SEQ ID NO: 39)
R587I-R	CCC AAG CGG GGT GAT GAC GGG GAT GTT (SEQ ID NO: 40)
R587I-F	AAC ATC CCC GTC ATC ACC CCG CTT GGG (SEQ ID NO: 41)
Xba-R	CTG CAG GTC GAC TCT AGA CTA TCA CTC CTT GGC GGA G (SEQ ID NO: 42)

[Table 19]

10X pfu buffer (SolGent)	5 μ l
dNTP (10 mM each)	2 μ l
F primer (10 pmol/ μ l)	2 μ l
R primer (10 pmol/ μ l)	2 μ l
Distilled water	36 μ l
Taq plasmid (E507K, R536K, R660V) (10 ng/ μ l)	2 μ l
Pfu polymerase	1 μ l
35 cycles (Ta=60 $^{\circ}$ C)	50 μ l

[0172] The PCR product was confirmed by electrophoresis, and thus, as shown in (b) FIG. 9, a band for each fragment was confirmed, indicating that a desired fragment was amplified.

4-2. In-fusion cloning

[0173] A Taq plasmid vector (E507K/R536K/R660V) was digested with restriction enzymes KpnI/XbaI at 37 $^{\circ}$ C for 4 hours under conditions shown in Table 20 and then purified (elution: 25 μ l), thereby preparing an open linear vector. Afterward, an in-fusion cloning reaction was performed under conditions shown in Table 21 at 37 $^{\circ}$ C for 15 minutes to

EP 3 653 729 A1

transform *E. coli* DH5 α or DH10 β , and then the transformed cell was screened in an ampicillin-containing medium. Plasmids prepared from the collected colonies were sequenced, thereby obtaining a R587I variation-introduced Taq DNA polymerase mutant ("E507K/R536K/R587I/R660V").

[Table 20]

10X CutSmart Vector (NEB)	2.5 μ l
Taq plasmid (E507K/R536K/R660V) (200 ng/ μ l)	21.5 μ l
Kpn I-HF (NEB)	0.5 μ l
Xba I (NEB)	0.5 μ l
25 μ l	

[Table 21]

5X EZ-fusion mix (Enzymomics)	2 μ l
Vector cleaved with Kpn I, Xba I (50 ng/ μ l)	1 μ l
F1 fragment (83 ng/ μ l)	1 μ l
F2 fragment (50 ng/ μ l)	1 μ l
Distilled water	5 μ l
10 μ l	

[Example 5] Performance of qPCR using "E507K/R536K/R587I/R660V" Taq polymerase

5-1. Discrimination of Q61H variations in KRAS gene

[0174] The Taq polymerase having the "E507K/R536K/R587I/R660V" variations obtained in Example 4 was used to confirm whether an ability of extending mismatched primers with respect to templates with Q61H SNPs in the KRAS gene was reduced. As a control, the Taq polymerase having "E507K/R536K/R660V" variations was used.

[0175] The template including a SNP was gDNA (104 copies, 33 ng/rxn) obtained from a HepG2 liver cancer cell line, and obtained by a typical DNA extraction method. It was confirmed that an entire detected target site corresponds to the NCBI reference sequence (NG_007524.1), and used as a wild-type (WT).

[0176] The sequence data of specific primers for the template is shown in Table 22 below.

[Table 22]

Primer Name		Sequence (5'-3')	Tm ($^{\circ}$ C)
KRAS Q61H	Forward_Q (24 mer)	GAT ATT CTC GAC ACA GCA GGT CAA (SEQ ID NO: 43)	64.2
	Forward_H (24mer)	GAT ATT CTC GAC ACA GCA GGT CAC (SEQ ID NO: 44)	64.4
	Reverse	ACA AAG AAA GCC CTC CCC AG (SEQ ID NO: 45)	64.2

[0177] Conditions for qPCR (Applied Biosystems 7500 Fast) are the same as shown in Table 14 in Example 3. Probes are labeled as shown in Table 23 below.

[Table 23]

Probe Name	Sequence (5' - 3')	Tm ($^{\circ}$ C)
Q61HFAM	TGC AAT GAG GGA CCA GTA CAT GAG G (SEQ ID NO: 46)	67.6

[0178] Reaction conditions are the same as shown in Table 16 in Example 3, and the composition of the reaction buffer is the same as in Table 24 below.

[Table 24]

Reaction buffer (1X)
50 mM Tris·Cl (pH 8.8)
2.5 mM MgCl ₂
60 mM KCl
2.5 mM (NH ₄) ₂ SO ₄
25 mM TMAC
0.1 % Tween 20
0.01 %BSA

[0179] The other components of the reaction solution except a specific primer were prepared as shown in Table 22 in two tubes, and each allele-specific primer was added thereto, thereby performing qPCR. Here, a difference in cycle (Ct) value at which combined fluorescent signals detected from the tubes reach the threshold fluorescence value calculated with AB 7500 software (v2.0.6) was analyzed. It is considered that, as the Ct value in the amplification by a mismatched primer is delayed, high gene variation specificity or allele specificity is exhibited. As a result of AS-qPCR, as shown in FIGS. 10a and 10b, compared to the control E507K/R536K/R660V, the Taq polymerase having E507K/R536K/R587I/R660V variations was increased in Δ Ct up to 5, indicating that the amplification by a mismatched primer was delayed.

[0180] The inventors further performed the above-described experiment once again using a primer shown in Table 25, which was manufactured by shortening the 24-mer primer of Table 22 to 18 mer. Except for using the composition of the reaction buffer in Table 26 below, all conditions are the same as those in the experiment using the 24-mer primer.

[Table 25]

Primer Name		Sequence (5' -3')	Tm (°C)
KRAS Q61H	Forward_Q (18 mer)	CTC GAC ACA GCA GGT CAA (SEQ ID NO: 47)	61.4
	Forward_H (18mer)	CTC GAC ACA GCA GGT CAC (SEQ ID NO: 48)	61.8
	Reverse	ACA AAG AAA GCC CTC CCC AG (SEQ ID NO: 49)	64.2

[Table 26]

Reaction buffer (1X)
50 mM Tris·Cl (pH 8.8)
2.5 mM MgCl ₂
15 mM (NH ₄) ₂ SO ₄
0.1 % Tween 20
0.01 %BSA

[0181] Consequently, as shown in FIGS. 10c and 10d, compared to the control E507K/R536K/R660V, the Taq polymerase having E507K/R536K/R587I/R660V variations can confirm that the amplification by a mismatched primer is delayed. Particularly, the Δ Ct of the R587I-introduced polymerase was more remarkably increased.

5-2. Discrimination of G13D variations in KRAS gene

[0182] The Taq polymerase having the "E507K/R536K/R587I/R660V" variations obtained in Example 4 was used to confirm whether an ability of extending mismatched primers with respect to templates with G13D SNPs in the KRAS gene was reduced. As a control, Taq polymerase having "E507K/R536K/R660V" variations was used.

[0183] The template including an SNP was gDNA (104 copies, 33 ng/rxn) obtained from a HepG2 liver cancer cell

EP 3 653 729 A1

line, and obtained by a typical DNA extraction method. It was confirmed that an entire detected target site corresponds to the NCBI reference sequence (NG_007524.1), and used as a wild-type (WT).

[0184] The sequence data of specific primers for the template is shown in Table 27 below.

[Table 27]

Primer Name		Sequence (5' -3')	Tm (□)
KRAS G13D	Forward	ATA AGG CCT GCT GAA AAT GAC (SEQ ID NO: 50)	61
	Reverse_ G (17mer)	GGC ACT CTT GCC TAC GC (SEQ ID NO: 51)	62.4
	Reverse_ D (17mer)	GGC ACT CTT GCC TAC GT (SEQ ID NO: 52)	61.2

[0185] Conditions for qPCR (Applied Biosystems 7500 Fast) are the same as shown in Table 14 in Example 3. Probes are labeled as shown in Table 28 below.

[Table 28]

Probe Name	Sequence (5' - 3')	Tm (□)
G1213_ R FAM	AGC TCC AAC TAC CAC AAG TTT ATA TTC AGT (SEQ ID NO: 53)	66.2

[0186] Reaction conditions are the same as shown in Table 16 in Example 3, and the composition of the reaction buffer is the same as in Table 24 in Example 5-1. The other components of the reaction solution except a specific primer were prepared as shown in Table 27 in two tubes, and each allele-specific primer was added thereto, thereby performing qPCR. Here, a difference in cycle (Ct) value at which combined fluorescent signals detected from the tubes reach the threshold fluorescence value calculated with AB 7500 software (v2.0.6) was analyzed. It is considered that, as the Ct value in the amplification by a mismatched primer is delayed, high gene variation specificity or allele specificity is exhibited.

[0187] As a result of AS-qPCR, as shown in FIG. 11, compared to the control E507K/R536K/R660V, the Taq polymerase having E507K/R536K/R587I/R660V variations confirmed that the amplification by a mismatched primer was delayed.

5-3. Discrimination of G12S variations in KRAS gene

[0188] The Taq polymerase having the "E507K/R536K/R587I/R660V" variations obtained in Example 4 was used to confirm whether an ability of extending mismatched primers with respect to templates having G13S SNPs in the KRAS gene was reduced. As a control, the Taq polymerase having "E507K/R536K/R660V" variations was used.

[0189] The template having an SNP was gDNA (104 copies, 33 ng/rxn) obtained from a HepG2 liver cancer cell line, and obtained by a typical DNA extraction method. It was confirmed that an entire detected target site corresponds to the NCBI reference sequence (NG_007524.1), and used as a wild-type (WT).

[0190] The sequence data of specific primers for the template is shown in Table 29 below.

[Table 29]

Primer Name		Sequence (5' -3')	Tm (□)
KRAS G12S	Forward_ G (23mer)	TAA ACT TGT GGT AGT TGG AGC TG (SEQ ID NO: 54)	62.6
	Forward_ S (23mer)	TAA ACT TGT GGT AGT TGG AGC TA (SEQ ID NO: 55)	61.6
	Reverse	CAT ATT CGT CCA CAA AAT GAT TCT GAA T (SEQ ID NO: 56)	63

[0191] Conditions for qPCR (Applied Biosystems 7500 Fast) are the same as shown in Table 14 in Example 3. Probes are labeled as shown in Table 30 below.

[Table 30]

Probe Name	Sequence (5' - 3')	Tm (□)
G1213F_FAM	AGC TGT ATC GTC AAG GCA CTC TTG C (SEQ ID NO: 57)	68.2

[0192] Reaction conditions are the same as shown in Table 16 in Example 3, and the composition of the reaction

buffer is the same as in Table 24 in Example 5-1. The other components of the reaction solution except a specific primer were prepared as shown in Table 29 in two tubes, and each allele-specific primer was added thereto, thereby performing qPCR. Here, a difference in cycle (Ct) value at which combined fluorescent signals detected from the tubes reach the threshold fluorescence value calculated with AB 7500 software (v2.0.6) was analyzed. It is considered that, as the Ct value in the amplification by a mismatched primer is delayed, high gene variation specificity or allele specificity is exhibited.

[0193] As a result of AS-qPCR, as shown in FIG. 12, compared to the control E507K/R536K/R660V, the Taq polymerase having E507K/R536K/R587I/R660V variations confirmed that the amplification by a mismatched primer was delayed.

5-4. Discrimination of L858R variations in EGFR gene

[0194] The Taq polymerase having the "E507K/R536K/R587I/R660V" variations obtained in Example 4 was used to confirm whether an ability of extending mismatched primers with respect to templates with L858R SNPs in EGFR gene was reduced. As a control, Taq polymerase having "E507K/R536K/R660V" variations was used.

[0195] The template including a SNP was gDNA (104 copies, 33 ng/rxn) obtained from a HepG2 liver cancer cell line, and obtained by a typical DNA extraction method. It was confirmed that an entire detected target site corresponds to the NCBI reference sequence (NG_007726.3), and used as a wild-type (WT).

[0196] The sequence data of specific primers for the template is shown in Table 31 below.

[Table 31]

Primer Name		Sequence (5'-3')	Tm (□)
EGFR L858R	Forward	ACC TGG CAG CCA GGA ACG TA (SEQ ID NO: 58)	67.8
	Reverse_L	GCA CCC AGC AGT TTG GCC A (SEQ ID NO: 59)	68.2
	Reverse_R	GCA CCC AGC AGT TTG GCC C (SEQ ID NO: 60)	67.7

[0197] Conditions for qPCR (Applied Biosystems 7500 Fast) are the same as shown in Table 14 in Example 3. Probes are labeled as shown in Table 32 below.

[Table 32]

Probe Name	Sequence (5' - 3')	Tm (□)
L858R FAM_R	CAG CAT GTC AAG ATC ACA GAT TTT GGG C (SEQ ID NO: 61)	67.8

[0198] Reaction conditions are the same as shown in Table 16 in Example 3, and the composition of the reaction buffer is the same as in Table 24 in Example 5-1. The other components of the reaction solution except a specific primer were prepared as shown in Table 31 in two tubes, and each allele-specific primer was added thereto, thereby performing qPCR. Here, a difference in cycle (Ct) value at which combined fluorescent signals detected from the tubes reach the threshold fluorescence value calculated with AB 7500 software (v2.0.6) was analyzed. It is considered that, as the Ct value in the amplification by a mismatched primer is delayed, high gene variation specificity or allele specificity is exhibited.

[0199] As a result of AS-qPCR, as shown in FIG. 13, compared to the control E507K/R536K/R660V, the Taq polymerase having E507K/R536K/R587I/R660V variations confirmed that the amplification by a mismatched primer was delayed.

[0200] As described above, it was confirmed that some of the Taq DNA polymerases having E507K/R536K/R587I/R660V variations according to the present invention, compared to the Taq polymerase having E507K/R536K/R660V variations, have excellent mismatch extension selectivity. Therefore, the Taq DNA polymerases having E507K/R536K/R587I/R660V variations according to the present invention are also expected to be usefully applied to the medical diagnosis of a disease and recombinant DNA studies.

[Example 6]

Optimization of KCl concentration in reaction buffer

[0201] In this example, to find a high cation concentration in a state in which the amplification by mismatching is delayed as much as possible, and the amplification efficiency by matching is not reduced, an optimal KCl concentration was confirmed by adjusting a KCl concentration in a PCR buffer.

[0202] The Taq polymerases having "E507K/R536K," "E507K/R660V" and "E507K/R536K/R660V" variations, respectively, obtained in Example 2 were used to compare a KCl concentration threshold with the Taq polymerase having the

EP 3 653 729 A1

E507K variation.

[0203] As a template having an SNP, rs1408799 was used, the genotype of the template was TT, and as a primer, an rs1408799 primer shown in Table 2 was used. qPCR (Applied Biosystems 7500 Fast) was performed under the conditions shown in Table 14, a dual-labeled probe is 1408799-FAM shown in Table 15, the reaction conditions are shown in Table 33, and the composition of the reaction buffer is shown in Table 34.

[Table 33]

5X Reaction buffer	4 μ l
dNTP (10 mM each)	0.5 μ l
Forward primer (2 μ M)	1 μ l
Reverse primer (2 μ M)	1 μ l
Nuclease-free distilled water	10 μ l
Acquired template (TT)	1 μ l
Taq polymerase (2 U/ μ l)	0.5 μ l
Dual-labeled probe (4 μ M)	2 μ l
20 μ l	

[Table 34]

Reaction buffer (1X)
50 mM Tris-Cl (pH 8.8)
2.5 mM MgCl ₂
x mM KCl
2.5 mM (NH ₄) ₂ SO ₄
0.1 % Tween 20
0.01 %BSA

[0204] Consequently, as shown in FIGS. 14a to 14d, it was confirmed that the E507K/R536K/R660V Taq polymerase has the lowest KCl concentration threshold, and the E507K/R536K and E507K/R660V have lower KCl concentration thresholds than E507K. Based on the result, to determine the optimal KCl concentration, an additional experiment was performed using the E507K/R536K/R660V Taq polymerase. A primer was the rs1408799-T-specific primer shown in Table 13, qPCR (Applied Biosystems 7500 Fast) was performed for 35 cycles under the conditions shown in Table 14, and reaction conditions are shown in Table 35.

[Table 35]

5X Reaction buffer	4 μ l
dNTP (10 mM each)	0.5 μ l
Forward primer (2 μ M)	1 μ l
Reverse primer (2 μ M)	1 μ l
Nuclease-free distilled water	12 μ l
Acquired template (TT)	1 μ l
E507K/R536K/R660V (2 U/ μ l)	0.5 μ l
20 μ l	

[0205] The composition of a reaction buffer for the control is shown in Table 36, and the composition of a reaction buffer for the experimental group is shown in Table 34. The (NH₄)₂SO₄ concentration was constantly fixed at 2.5 mM,

and the KCl concentration varied.

[Table 36]

Control buffer (1X)
50 mM Tris·Cl (pH 8.8)
1M betaine
2.5 mM MgCl ₂
50 mM KCl
2.5 mM (NH ₄) ₂ SO ₄
0.1 % Tween 20
0.01 %BSA

[0206] Amplification was performed under the above-mentioned conditions, and the PCR product was identified by electrophoresis, thereby confirming that, as shown in FIG. 15, an optimal KCl concentration in a state in which the amplification by mismatching is delayed as much as possible, and the amplification efficiency by matching is not reduced is 75 mM.

[Example 7]

Optimization of (NH₄)₂SO₄ concentration in reaction buffer

[0207] In this example, based on the result of Example 4, the optimal (NH₄)₂SO₄ concentration was confirmed by constantly fixing a KCl concentration in a reaction buffer at 75 mM and variously changing a (NH₄)₂SO₄ concentration. As a primer, the rs1408799-T-specific primer shown in Table 13 was used, qPCR (Applied Biosystems 7500 Fast) was performed for 35 cycles under the conditions shown in Table 14, reaction conditions are shown in Table 35, and the composition of a reaction buffer for the control is shown in Table 36.

[0208] Consequently, as shown in FIG. 16, it was confirmed that an optimal (NH₄)₂SO₄ concentration is 5 mM.

[0209] Based on the result, an amplification delay effect caused by mismatching was further confirmed by constantly fixing the KCl concentration in the reaction buffer at 75 mM, and setting the (NH₄)₂SO₄ concentration to approximately 5 mM (each of 2.5 mM, 5 mM and 10 mM).

[0210] As a primer, the rs1408799 primer shown in Table 13 was used, a dual-labeled probe is 1408799-FAM shown in Table 15, and reaction conditions are shown in Table 37 below.

[Table 37]

5X Reaction buffer	4 µl
dNTP (10 mM each)	0.5 µl
Forward primer (2 µM)	1 µl
Reverse primer (2 µM)	1 µl
Nuclease-free distilled water	10 µl
Acquired template (TT)	1 µl
E507K/R536K/R660V (2 U/µl)	0.5 µl
Dual-labeled probe (4 µM)	2 µl
20 µl	

[0211] Consequently, as shown in FIG. 17, when the (NH₄)₂SO₄ concentration was 10 mM, the Ct value difference was the largest, but Ct was a little delayed and a peak was tilted in the amplification caused by matching, and the optimal (NH₄)₂SO₄ concentration was determined to be 5 mM. By combining the results of Examples 6 and 7, it was confirmed that the optimal composition of a reaction buffer contains 50 mM Tris·Cl, 2.5mM MgCl₂, 75 mM KCl, 5 mM (NH₄)₂SO₄, 0.1% Tween 20 and 0.01% BSA.

[Example 8]

Addition of TMAC to reaction buffer and optimization of TMAC concentration

[0212] In this example, the optimal concentration was confirmed by adding TMAC to a reaction buffer. Based on the results of Examples 6 and 7, the optimal TMAC concentration was determined by constantly fixing a KCl concentration at 75 mM and a $(\text{NH}_4)_2\text{SO}_4$ concentration at 5 mM, and variously changing a TMAC concentration.

[0213] A E507K/R536K or E507K/R536K/R660V Taq polymerase was used, and as a template having an SNP, rs1408799 was used. The genotype of the template was TT, and as a primer, the rs1408799 primer shown in Table 13 was used. qPCR (Applied Biosystems 7500 Fast) was performed under the conditions shown in Table 14, a dual-labeled probe is 1408799-FAM shown in Table 15, and reaction conditions are shown in Table 37.

[0214] Consequently, as shown in FIGS. 18a and 18b, it was confirmed that, for the E507K/R536K Taq polymerase, the optimal TMAC concentration is 60 mM, and for the E507K/R536K/R660V Taq polymerase, the optimal TMAC concentration is 25 mM. When the TMAC concentration is very high, amplification efficiency was reduced.

[Example 9]

Optimization of KCl, $(\text{NH}_4)_2\text{SO}_4$ and TMAC concentrations in reaction buffer

[0215] In this Example, based on the result shown in Example 8, the optimal KCl, $(\text{NH}_4)_2\text{SO}_4$ and TMAC concentrations in a reaction buffer were confirmed using the E507K/R536K/R660V Taq polymerase.

[0216] Specifically, the TMAC concentration was constantly fixed at 25 mM, the $(\text{NH}_4)_2\text{SO}_4$ concentration was constantly fixed at 2.5 mM, and then the KCl concentration was changed to 20, 40, 60 or 80 mM. An experiment was performed on two SNPs of rs1015362 and rs4911414, and the genotype of the template is shown in Table 12, primers were the rs1015362 and rs4911414 primers shown in Table 13, qPCR (Applied Biosystems 7500 Fast) was performed under the conditions shown in Table 14, a dual-labeled probe is 1408799-FAM shown in Table 15, and reaction conditions are shown in Table 37.

[0217] Consequently, as shown in FIGS. 19a and 19b the optimal KCl concentration for two SNPs was 60 mM, and it can be observed that when the KCl concentration was 80 mM, amplification efficiency was reduced.

[0218] From the above-described results, it was confirmed that the optimal KCl concentration in the reaction buffer was 60 mM, the optimal $(\text{NH}_4)_2\text{SO}_4$ concentration was 2.5 mM, and the optimal TMAC concentration was 25 mM, and in further detail, for the E507K/R536K polymerase, 75 mM KCl, 5 mM $(\text{NH}_4)_2\text{SO}_4$ and 60 mM TMAC were most effectively used, and for the E507K/R536K/R660V polymerase, 60 mM KCl, 2.5 mM $(\text{NH}_4)_2\text{SO}_4$ and 25 mM TMAC were most effectively used.

[Industrial Applicability]

[0219] Since the DNA polymerase with increased gene variation specificity according to the present invention has a higher mismatch-to-match extension selectivity than conventional Taq polymerase, reliable gene variation-specific amplification is possible without any substrate modification. The present invention provides an optimal PCR buffer composition that allows the proper function of a DNA polymerase with increased gene variation specificity to be effectively exhibited, and reliable gene variation-specific amplification is possible by considerably increasing the activity of the DNA polymerase using the DNA polymerase with increased gene variation specificity. Moreover, a kit including a PCR buffer composition and/or the DNA polymerase with increased gene variation specificity according to the present invention can effectively detect a gene variation or SNP, and thus can be usefully applied to the medical diagnosis of a disease and recombinant DNA studies.

<110> GeneCast Co., Ltd.

<120> DNA POLYMERASES WITH INCREASED MUTATION SPECIFIC AMPLIFICATION

<130> 1062317

<160> 61

<170> KopatentIn 2.0

<210> 1

EP 3 653 729 A1

<211> 832

<212> PRT

<213> Artificial Sequence

5 <220>

<223> Thermus aquaticus DNA polymerase (Taq)

10 <400> 1

	Met	Arg	Gly	Met	Leu	Pro	Leu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu	Leu	
	1				5					10					15		
15	Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Leu	Lys	Gly	
				20					25					30			
	Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala	
				35				40					45				
20	Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val	
		50					55					60					
	Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly	Gly	
	65					70					75					80	
25	Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu	
					85					90					95		
	Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Leu	Ala	Arg	Leu	Glu	
30				100					105					110			
	Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys	Lys	
			115					120					125				
	Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys	Asp	
35		130					135					140					
	Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu	Gly	
	145					150					155					160	
40	Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg	Pro	
					165					170					175		
	Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp	Asn	
				180					185					190			
45	Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu	Leu	
			195					200					205				
	Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Leu	Lys	Asn	Leu	Asp	Arg	Leu	
		210					215					220					
50	Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Leu	Ala	His	Met	Asp	Asp	Leu	Lys	
55																	

EP 3 653 729 A1

	225				230					235				240		
	Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu	Val
					245					250					255	
5	Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala	Phe
				260					265					270		
	Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Leu	Leu	His	Glu	Phe	Gly	Leu	Leu
			275					280					285			
10	Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly
			290				295					300				
	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp
	305					310					315					320
15	Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro
				325						330					335	
	Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu
				340					345					350		
20	Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro
			355					360					365			
	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn
		370					375					380				
	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu
	385					390					395					400
	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu
					405					410					415	
30	Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu
				420					425					430		
	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly
			435					440					445			
	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala
		450					455					460				
40	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His
	465					470					475					480
	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp
					485					490					495	
45	Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	Arg
				500					505					510		
	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile
			515					520					525			
50	Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr
		530					535					540				
	Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu
	545					550					555					560
55	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser

EP 3 653 729 A1

	565				570				575							
5	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln
				580												590
	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala
				595				600								605
10	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly
		610					615					620				
	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr
		625				630					635					640
15	Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro
					645					650					655	
	Leu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly
				660						665				670		
20	Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu
			675					680						685		
	Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg
		690					695					700				
25	Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val
		705				710					715					720
	Glu	Thr	Leu	Phe	Gly	Arg	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	Arg
30					725					730					735	
	Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met	Pro
				740						745				750		
35	Val	Gln	Gly	Thr	Ala	Ala	Asp	Leu	Met	Lys	Leu	Ala	Met	Val	Lys	Leu
			755					760						765		
	Phe	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Leu	Leu	Gln	Val	His
		770					775					780				
40	Asp	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val	Ala
		785				790					795					800
	Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val	Pro
				805						810					815	
45	Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys	Glu
				820						825				830		

<210> 2

<211> 832

50 <212> PRT

<213> Artificial Sequence

<220>

<223> Taq E507K

55

<400> 2

EP 3 653 729 A1

	Met	Arg	Gly	Met	Leu	Pro	Leu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu	Leu	
	1				5					10					15		
5	Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Leu	Lys	Gly	
				20					25					30			
	Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala	
			35					40					45				
10	Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val	
		50					55					60					
	Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly	Gly	
	65					70					75					80	
15	Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu	
					85					90					95		
	Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Leu	Ala	Arg	Leu	Glu	
				100					105					110			
20	Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys	Lys	
			115					120					125				
	Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys	Asp	
		130					135						140				
25	Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu	Gly	
	145					150					155					160	
	Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg	Pro	
					165					170					175		
30	Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp	Asn	
				180					185					190			
	Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu	Leu	
35			195					200					205				
	Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Leu	Lys	Asn	Leu	Asp	Arg	Leu	
		210					215					220					
40	Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Leu	Ala	His	Met	Asp	Asp	Leu	Lys	
	225					230					235					240	
	Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu	Val	
				245					250						255		
45	Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala	Phe	
				260					265					270			
	Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Leu	Leu	His	Glu	Phe	Gly	Leu	Leu	
			275					280					285				
50	Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly	
		290					295					300					
	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp	
	305					310					315					320	
55	Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro	
					325					330					335		

EP 3 653 729 A1

	Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu	
				340					345					350			
5	Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro	
			355					360					365				
	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn	
		370					375					380					
10	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu	
	385					390					395					400	
	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu	
					405					410					415		
15	Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu	
				420					425					430			
	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly	
			435					440					445				
20	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala	
		450					455					460					
	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His	
	465					470					475					480	
25	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp	
					485					490					495		
	Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Lys	Lys	Thr	Gly	Lys	Arg	
				500					505					510			
30	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile	
			515					520					525				
	Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr	
35		530					535					540					
	Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu	
	545					550					555					560	
	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser	
40					565					570					575		
	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln	
				580					585					590			
45	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala	
			595					600					605				
	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly	
		610					615					620					
50	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr	
	625					630					635					640	
	Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro	
					645					650					655		
55	Leu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly	
				660					665					670			

EP 3 653 729 A1

	Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu	
			675					680					685				
5	Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg	
		690					695					700					
	Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val	
	705					710					715					720	
10	Glu	Thr	Leu	Phe	Gly	Arg	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	Arg	
					725					730					735		
	Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met	Pro	
				740					745					750			
15	Val	Gln	Gly	Thr	Ala	Ala	Asp	Leu	Met	Lys	Leu	Ala	Met	Val	Lys	Leu	
			755					760					765				
	Phe	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Leu	Leu	Gln	Val	His	
20		770					775					780					
	Asp	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val	Ala	
	785					790					795					800	
	Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val	Pro	
25				805						810					815		
	Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys	Glu	
				820					825					830			
30	<210> 3																
	<211> 832																
	<212> PRT																
	<213> Artificial Sequence																
35	<220>																
	<223> Taq R536K																
	<400> 3																
40	Met	Arg	Gly	Met	Leu	Pro	Leu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu	Leu	
	1				5					10					15		
	Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Leu	Lys	Gly	
				20					25					30			
45	Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala	
				35				40					45				
	Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val	
50		50					55					60					
	Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly	Gly	
	65					70					75					80	
	Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu	
55					85					90					95		
	Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Leu	Ala	Arg	Leu	Glu	
				100					105					110			

EP 3 653 729 A1

	Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys	Lys	
			115					120					125				
5	Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys	Asp	
			130				135					140					
	Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu	Gly	
	145					150					155					160	
10	Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg	Pro	
					165					170					175		
	Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp	Asn	
				180					185					190			
15	Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu	Leu	
			195					200					205				
	Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Leu	Lys	Asn	Leu	Asp	Arg	Leu	
	210						215					220					
20	Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Leu	Ala	His	Met	Asp	Asp	Leu	Lys	
	225					230					235					240	
	Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu	Val	
				245					250						255		
25	Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala	Phe	
				260					265					270			
	Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Leu	Leu	His	Glu	Phe	Gly	Leu	Leu	
			275					280					285				
30	Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly	
	290						295					300					
	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp	
	305					310					315					320	
35	Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro	
					325					330					335		
	Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu	
				340					345					350			
	Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro	
			355					360					365				
45	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn	
	370						375					380					
	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu	
	385					390					395					400	
50	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu	
					405					410					415		
	Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu	
				420				425						430			
55	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly	
			435					440					445				

EP 3 653 729 A1

	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala	
	450						455					460					
5	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His	
	465					470					475					480	
	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp	
					485					490					495		
10	Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	Arg	
				500					505					510			
	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile	
			515					520					525				
15	Val	Glu	Lys	Ile	Leu	Gln	Tyr	Lys	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr	
	530						535					540					
	Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu	
	545					550					555					560	
20	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser	
					565					570					575		
	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln	
				580					585					590			
25	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala	
				595				600					605				
	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly	
30		610					615					620					
	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr	
	625					630					635					640	
	Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro	
35				645						650					655		
	Leu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly	
				660					665					670			
	Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu	
40			675					680					685				
	Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg	
			690				695					700					
45	Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val	
	705					710					715					720	
	Glu	Thr	Leu	Phe	Gly	Arg	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	Arg	
				725						730				735			
50	Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met	Pro	
				740					745					750			
	Val	Gln	Gly	Thr	Ala	Ala	Asp	Leu	Met	Lys	Leu	Ala	Met	Val	Lys	Leu	
			755				760						765				
55	Phe	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Leu	Leu	Gln	Val	His	
				770			775					780					

EP 3 653 729 A1

	Asp	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val	Ala	785	790	795	800
5	Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val	Pro	805	810	815	
	Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys	Glu	820	825	830	
10	<210> 4																			
	<211> 832																			
	<212> PRT																			
	<213> Artificial Sequence																			
15	<220>																			
	<223> Taq R660V																			
	<400> 4																			
20	Met	Arg	Gly	Met	Leu	Pro	Leu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu	Leu	1	5	10	15
	Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Leu	Lys	Gly	20	25	30	
25	Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala	35	40	45	
	Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val	50	55	60	
30	Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly	Gly	65	70	75	80
	Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu	85	90	95	
35	Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Leu	Ala	Arg	Leu	Glu	100	105	110	
	Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys	Lys	115	120	125	
	Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys	Asp	130	135	140	
45	Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu	Gly	145	150	155	160
	Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg	Pro	165	170	175	
50	Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp	Asn	180	185	190	
	Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu	Leu	195	200	205	
55	Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Leu	Lys	Asn	Leu	Asp	Arg	Leu				

EP 3 653 729 A1

[illegible]

EP 3 653 729 A1

	545				550					555				560		
	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser
					565					570					575	
5																
	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln
				580					585					590		
	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala
10				595				600					605			
	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly
		610					615					620				
15	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr
	625					630					635					640
	Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro
					645					650					655	
20	Leu	Met	Arg	Val	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly
				660					665					670		
	Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu
			675					680					685			
25																
	Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg
		690					695					700				
	Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val
30	705					710				715						720
	Glu	Thr	Leu	Phe	Gly	Arg	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	Arg
					725					730					735	
	Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met	Pro
35				740					745					750		
	Val	Gln	Gly	Thr	Ala	Ala	Asp	Leu	Met	Lys	Leu	Ala	Met	Val	Lys	Leu
			755					760					765			
40	Phe	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Leu	Leu	Gln	Val	His
	770						775					780				
	Asp	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val	Ala
	785					790					795					800
45																
	Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val	Pro
					805					810					815	
	Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys	Glu
50				820					825					830		

<210> 5
 <211> 832
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Taq R536K/R660V

EP 3 653 729 A1

<400> 5
Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15
5 Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly
20 25 30
Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala
35 40 45
10 Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val
50 55 60
Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly
65 70 75 80
15 Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu
85 90 95
Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu
100 105 110
20 Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys
115 120 125
Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp
130 135 140
25 Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly
145 150 155 160
30 Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro
165 170 175
Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn
180 185 190
35 Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu
195 200 205
Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu
210 215 220
40 Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys
225 230 235 240
Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val
245 250 255
45 Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe
260 265 270
Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu
275 280 285
50 Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly
290 295 300
55 Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp
305 310 315 320

EP 3 653 729 A1

	Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro	
					325					330					335		
5	Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu	
				340					345					350			
	Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro	
			355					360					365				
10	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn	
		370					375					380					
	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu	
	385					390					395					400	
15	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu	
					405					410					415		
	Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu	
				420					425					430			
20	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly	
			435					440					445				
	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala	
		450					455					460					
25	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His	
	465					470					475					480	
	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp	
30					485				490						495		
	Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys	Arg	
				500					505					510			
	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile	
35			515					520					525				
	Val	Glu	Lys	Ile	Leu	Gln	Tyr	Lys	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr	
		530					535					540					
	Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu	
40						550					555					560	
	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser	
					565				570						575		
45	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln	
				580				585						590			
	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala	
			595					600					605				
50	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly	
		610					615					620					
	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr	
	625					630					635					640	
55	Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro	
					645					650					655		

EP 3 653 729 A1

	Leu	Met	Arg	Val	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly	
				660					665					670			
5	Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu	
			675					680					685				
	Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg	
		690					695					700					
10	Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val	
	705					710					715					720	
	Glu	Thr	Leu	Phe	Gly	Arg	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	Arg	
					725					730					735		
15	Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met	Pro	
				740					745					750			
	Val	Gln	Gly	Thr	Ala	Ala	Asp	Leu	Met	Lys	Leu	Ala	Met	Val	Lys	Leu	
			755					760					765				
20	Phe	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Leu	Leu	Gln	Val	His	
		770					775					780					
	Asp	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val	Ala	
25		785				790					795					800	
	Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val	Pro	
				805						810					815		
30	Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys	Glu	
				820					825					830			
	<210> 6																
	<211> 832																
	<212> PRT																
35	<213> Artificial Sequence																
	<220>																
	<223> Taq E507K/R536K																
40	<400> 6																
	Met	Arg	Gly	Met	Leu	Pro	Leu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu	Leu	
	1				5					10					15		
45	Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Leu	Lys	Gly	
				20					25					30			
	Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala	
			35					40					45				
50	Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val	
		50					55					60					
	Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly	Gly	
55		65				70					75					80	
	Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu	
					85					90					95		

EP 3 653 729 A1

	Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Leu	Ala	Arg	Leu	Glu	
				100					105					110			
5	Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys	Lys	
			115					120					125				
	Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys	Asp	
		130					135					140					
10	Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu	Gly	
	145					150					155					160	
	Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg	Pro	
					165					170					175		
15	Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp	Asn	
				180					185					190			
	Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu	Leu	
			195					200					205				
20	Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Leu	Lys	Asn	Leu	Asp	Arg	Leu	
		210					215					220					
	Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Leu	Ala	His	Met	Asp	Asp	Leu	Lys	
	225					230					235					240	
25	Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu	Val	
				245						250					255		
	Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala	Phe	
30			260						265					270			
	Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Leu	Leu	His	Glu	Phe	Gly	Leu	Leu	
			275					280					285				
35	Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly	
		290					295					300					
	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp	
	305					310					315					320	
40	Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro	
					325					330					335		
	Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu	
				340					345					350			
45	Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro	
			355					360					365				
	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn	
		370					375					380					
50	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu	
	385					390					395					400	
	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu	
					405					410					415		
55	Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu	
				420					425					430			

EP 3 653 729 A1

	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly	
			435					440					445				
5	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala	
			450				455					460					
	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His	
						470					475					480	
10	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp	
					485					490					495		
	Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Lys	Lys	Thr	Gly	Lys	Arg	
				500					505					510			
15	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile	
			515					520					525				
	Val	Glu	Lys	Ile	Leu	Gln	Tyr	Lys	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr	
			530				535					540					
20	Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu	
					550						555					560	
	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser	
					565					570					575		
25	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln	
				580					585					590			
	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala	
			595					600					605				
30	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly	
		610					615					620					
	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr	
35		625				630					635					640	
	Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro	
				645						650					655		
40	Leu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly	
				660					665					670			
	Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu	
			675					680					685				
45	Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg	
		690					695					700					
	Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val	
		705				710					715					720	
50	Glu	Thr	Leu	Phe	Gly	Arg	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	Arg	
					725					730					735		
	Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met	Pro	
				740					745					750			
55	Val	Gln	Gly	Thr	Ala	Ala	Asp	Leu	Met	Lys	Leu	Ala	Met	Val	Lys	Leu	
			755					760					765				

EP 3 653 729 A1

	Phe	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Leu	Leu	Gln	Val	His
	770						775					780				
5	Asp	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val	Ala
	785					790					795					800
	Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val	Pro
				805						810					815	
10	Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys	Glu
				820					825					830		
	<210> 7															
	<211> 832															
15	<212> PRT															
	<213> Artificial Sequence															
	<220>															
20	<223> Taq E507K/R660V															
	<4> 7															
	Met	Arg	Gly	Met	Leu	Pro	Leu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu	Leu
25	1				5					10					15	
	Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Leu	Lys	Gly
				20					25					30		
	Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala
30			35					40					45			
	Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val
	50						55				60					
35	Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly	Gly
	65					70					75					80
	Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu
					85					90					95	
40	Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Leu	Ala	Arg	Leu	Glu
				100					105					110		
	Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys	Lys
45			115					120					125			
	Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys	Asp
	130						135					140				
	Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu	Gly
50	145					150					155					160
	Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg	Pro
				165						170					175	
55	Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp	Asn
				180					185					190		
	Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu	Leu

EP 3 653 729 A1

	195					200					205					
	Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Leu	Lys	Asn	Leu	Asp	Arg	Leu
	210						215					220				
5	Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Leu	Ala	His	Met	Asp	Asp	Leu	Lys
	225					230					235					240
	Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu	Val
10					245					250					255	
	Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala	Phe
				260					265					270		
	Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Leu	Leu	His	Glu	Phe	Gly	Leu	Leu
15			275					280					285			
	Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly
	290						295					300				
	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp
20	305					310					315					320
	Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro
					325					330					335	
	Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu
25				340					345					350		
	Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro
			355					360					365			
	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn
30		370					375					380				
	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu
	385					390					395					400
	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu
35					405					410					415	
	Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu
				420					425					430		
40	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly
			435					440					445			
	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala
45			450				455					460				
	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His
	465					470					475					480
	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp
50					485					490					495	
	Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Lys	Lys	Thr	Gly	Lys	Arg
				500					505					510		
	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile
55			515					520					525			
	Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr

EP 3 653 729 A1

	530		535		540												
5	Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu	
	545					550					555					560	
	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser	
					565					570					575		
10	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln	
				580					585					590			
	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala	
				595				600					605				
15	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly	
	610						615					620					
	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr	
	625					630					635					640	
20	Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro	
					645					650					655		
	Leu	Met	Arg	Val	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly	
				660					665					670			
25	Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu	
			675					680					685				
	Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val	Arg	
30		690					695					700					
	Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr	Val	
	705					710					715					720	
	Glu	Thr	Leu	Phe	Gly	Arg	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	Arg	
35				725					730					735			
	Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met	Pro	
				740					745					750			
40	Val	Gln	Gly	Thr	Ala	Ala	Asp	Leu	Met	Lys	Leu	Ala	Met	Val	Lys	Leu	
		755						760					765				
	Phe	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Leu	Leu	Gln	Val	His	
	770						775					780					
45	Asp	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val	Ala	
	785					790					795					800	
	Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val	Pro	
				805						810					815		
50	Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys	Glu	
				820					825					830			

<210> 8

<211> 832

<212> PRT

<213> Artificial Sequence

EP 3 653 729 A1

<220>

<223> Taq E507K/R536K/R660V

<400> 8

5

Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15

10

Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly
20 25 30

Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala
35 40 45

15

Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val
50 55 60

Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly
65 70 75 80

20

Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu
85 90 95

Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu
100 105 110

25

Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys
115 120 125

Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp
130 135 140

30

Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly
145 150 155 160

35

Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro
165 170 175

Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn
180 185 190

40

Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu
195 200 205

Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu
210 215 220

45

Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys
225 230 235 240

Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val
245 250 255

50

Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe
260 265 270

Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu
275 280 285

55

Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly
290 295 300

EP 3 653 729 A1

	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp	
	305					310					315					320	
5	Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro	
					325					330					335		
	Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu	
				340					345					350			
10	Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro	
			355					360					365				
	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn	
		370					375					380					
15	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu	
	385					390					395					400	
	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu	
					405					410					415		
20	Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu	
				420					425					430			
	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly	
			435					440					445				
25	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala	
		450					455					460					
	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His	
	465					470					475					480	
30	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp	
					485					490					495		
	Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Glu	Lys	Lys	Thr	Gly	Lys	Arg	
				500					505					510			
35	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile	
			515					520					525				
	Val	Glu	Lys	Ile	Leu	Gln	Tyr	Lys	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr	
		530					535					540					
	Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu	
	545					550					555					560	
45	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser	
					565					570					575		
	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly	Gln	
				580					585					590			
50	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala	
			595					600					605				
	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly	
		610					615					620					
55	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr	
	625					630					635					640	

EP 3 653 729 A1

	Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro	
	645 650 655	
5	Leu Met Arg Val Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly	
	660 665 670	
	Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu	
	675 680 685	
10	Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg	
	690 695 700	
	Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val	
	705 710 715 720	
15	Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg	
	725 730 735	
	Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro	
20	740 745 750	
	Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu	
	755 760 765	
	Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His	
25	770 775 780	
	Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala	
	785 790 795 800	
30	Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro	
	805 810 815	
	Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu	
	820 825 830	

35 <210> 9
 <211> 2499
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> Thermus aquaticus DNA polymerase (Taq)

<400> 9

45	atgaggggga tgctgccct ctttgagccc aagggccggg tcctcctggt ggacggccac	60
	cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg	120
50	gtgcagggcg tctacggctt cgccaagagc ctctcaagg ccctcaagga ggacggggac	180
	gcggtgatcg tgggtcttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg	240
	tacaaggcgg gccgggcccc cacgccggag gactttcccc ggcaactcgc cctcatcaag	300
55	gagctggtgg acctcctggg gctggcgcg ctcgaggtcc cgggctacga ggcggacgac	360
	gtcctggcca gcctggccaa gaaggcggaa aaggagggt acgaggtccg catcctcacc	420

EP 3 653 729 A1

	gccgacaaag acctttacca gctcctttcc gaccgcatcc acgtcctcca ccccgagggg	480
	tacctcatca ccccggcctg gctttgggaa aagtacggcc tgaggcccga ccagtgggcc	540
5	gactaccggg ccctgaccgg ggacgagtc gacaaccttc ccgggggtcaa gggcatcggg	600
	gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaagccct cctcaagaac	660
	ctggaccggc tgaagcccg catccgggag aagatcctgg cccacatgga cgatctgaag	720
10	ctctcctggg acctggccaa ggtgcgccacc gacctgcccc tggagggtgga cttcgccaaa	780
	aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc	840
	ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc	900
15	ccgccggaag gggccttcgt gggcctttgtg ctttcccgca aggagcccat gtgggccgat	960
	cttctggccc tggccgccgc cagggggggc cgggtccacc gggccccga gccttataaa	1020
	gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc	1080
20	ctgagggaag gccttggcct cccgccggc gacgaccca tgctcctcgc ctacctcctg	1140
	gacccttcca acaccacccc cgaggggggtg gcccggcgct acggcgggga gtggacggag	1200
25	gaggcggggg agcgggccgc cctttccgag aggctcttcg ccaacctgtg ggggaggctt	1260
	gagggggagg agaggctcct ttggctttac cgggaggtgg agaggccct ttcgctgtc	1320
	ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc	1380
30	ctggagggtg ccgaggagat cgcgcgcctc gaggccgagg tcttccgcct ggccggccac	1440
	cccttcaacc tcaactcccg ggaccagctg gaaaggggtcc tctttgacga gctagggctt	1500
	cccgccatcg gcaagacgga gaagaccggc aagcgctcca ccagcgccgc cgtcctggag	1560
35	gccctccgcg agggccaccc catcgtggag aagatcctgc agtaccggga gctcaccaag	1620
	ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac gggccgcctc	1680
	cacacccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac	1740
40	ctccagaaca tccccgtccg caccgccctt gggcagagga tccgcccggc cttcatcgcc	1800
	gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc	1860
	cacctctccg gcgacgagaa cctgatccgg gtcttccagg aggggcggga catccacacg	1920
45	gagaccgcca gctggatgtt cggcgtcccc cgggaggccg tggacccct gatgcgccg	1980
	gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctccag	2040
	gagctagcca tcccttacga ggaggccag gccttcattg agcgctactt tcagagcttc	2100
50	cccaagggtg gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg	2160
	gagaccctct tcggccgccg ccgctacgtg ccagacctag agggccgggt gaagagcgtg	2220
55	cgggaggcgg ccgagcgcac ggccttcaac atgccgtcc agggcacccg cgcgacctc	2280
	atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc	2340

EP 3 653 729 A1

	cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc	2400
	cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag	2460
5	gtggggatag gggaggactg gctctccgcc aaggagtga	2499

<210> 10

<211> 2499

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Taq E507K

15 <400> 10

20

25

30

35

40

45

50

55

EP 3 653 729 A1

	atgaggggga tgctgcccct ctttgagccc aagggccggg tcctcctggt ggacggccac	60
	cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg	120
5	gtgcaggcgg tctacggctt cgccaagagc ctctcaagg ccctcaagga ggacggggac	180
	gcggtgatcg tgggtctttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg	240
10	tacaaggcgg gccgggcccc cagcccgag gactttcccc ggcaactcgc cctcatcaag	300
	gagctggtgg acctcctggg gctggcgcg ctcgagggtcc cgggctacga ggcggacgac	360
	gtcctggcca gcctggccaa gaaggcggaa aaggagggtc acgagggtccg catcctcacc	420
15	gccgacaaag acctttacca gctcctttcc gaccgcatcc acgtcctcca ccccgagggg	480
	tacctcatca ccccgccctg gctttgggaa aagtacggcc tgaggcccga ccagtgggcc	540
	gactaccggg ccctgaccgg ggacgaggtcc gacaaccttc ccgggggtcaa gggcatcggg	600
20	gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaaaccct cctcaagaac	660
	ctggaccggc tgaagcccg ccatccgggag aagatcctgg ccacatgga cgatctgaag	720
25	ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggagggtgga cttcgccaaa	780
	aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc	840
	ctctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc	900
30	ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat	960
	cttctggccc tggccgccc cagggggggc cgggtccacc gggccccga gccttataaa	1020
	gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc	1080
35	ctgagggaag gccttggcct cccgcccggc gacgacccca tgctcctcgc ctacctcctg	1140
	gacccttcca acaccacccc cgaggggggtg gcccggcgct acggcgggga gtggacggag	1200
	gaggcggggg agcgggccc cctttccgag aggctcttcg ccaacctgtg ggggaggctt	1260
40	gagggggagg agaggctcct ttggctttac cgggaggtgg agaggcccct ttccgctgtc	1320
	ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc	1380

45

50

55

EP 3 653 729 A1

	ctggaggtgg ccgaggagat cgcccgctc gagggcgagg tcttccgcct ggccggccac	1440
	cccttcaacc tcaactcccg ggaccagctg gaaaggggtcc tctttgacga gctagggctt	1500
5	cccgccatcg gcaagacgaa aaagaccggc aagcgctcca ccagcgccgc cgtcctggag	1560
	gccctccgcg agggccaccc catcgtggag aagatcctgc agtaccggga gctcaccaag	1620
10	ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac gggccgcctc	1680
	cacacccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac	1740
	ctccagaaca tccccgtccg caccocgctt gggcagagga tccgcggggc cttcatcgcc	1800
15	gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc	1860
	cacctctccg gcgacgagaa cctgatccgg gtcttccagg aggggcggga catccacacg	1920
	gagaccgcca gctggatggt cggcgtcccc cgggaggccg tggaccccct gatgcgccgg	1980
20	gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag	2040
	gagctagcca tcccttacga ggaggcccag gccttcattg agcgctactt tcagagcttc	2100
	cccaaggtgc gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg	2160
25	gagaccctct tcggccgccc ccgctacgtg ccagacctag agggccgggt gaagagcgtg	2220
	cgggaggcgg ccgagcgcat ggccttcaac atgccgtcc agggcaccgc cgccgacctc	2280
30	atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc	2340
	cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc	2400
	cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag	2460
35	gtggggatag gggaggactg gctctccgcc aaggagtga	2499

<210> 11

<211> 2499

<212> DNA

40 <213> Artificial Sequence

<220>

<223> Taq R536K

45 <400> 11

50

55

EP 3 653 729 A1

	atgaggggga tgctgccct ctttgagccc aagggccggg tcctcctggt ggacggccac	60
	cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg	120
5	gtgcaggcgg tctacggctt cgccaagagc ctctcaagg ccctcaagga ggacggggac	180
	gcggtgatcg tgggtcttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg	240
10	tacaaggcgg gccggggcccc cacgccggag gactttcccc ggcaactcgc cctcatcaag	300
	gagctggtgg acctcctggg gctggcgcg ctcgaggtcc cgggctacga ggcggacgac	360
	gtcctggcca gcctggccaa gaaggcggaa aaggagggct acgaggtccg catcctcacc	420
15		
20		
25		
30		
35		
40		
45		
50		
55		

EP 3 653 729 A1

	gccgacaaag acctttacca gctcctttcc gaccgcatcc acgtcctcca ccccgagggg	480
	tacctcatca ccccggcctg gctttgggaa aagtacggcc tgaggcccgga ccagtgggcc	540
5	gactaccggg ccctgaccgg ggacgagtcc gacaaccttc ccgggggtcaa gggcatcggg	600
	gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaagccct cctcaagaac	660
	ctggaccggc tgaagcccg ccatccgggag aagatcctgg ccacatgga cgatctgaag	720
10	ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggaggtgga ctctgccaaa	780
	aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc	840
	ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc	900
15	ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat	960
	cttctggccc tggccgccc cagggggggc cggtccacc gggccccga gccttataaa	1020
20	gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc	1080
	ctgagggaaag gccttggcct cccgcccggc gacgaccca tgctcctcgc ctacctctg	1140
	gacccttcca acaccacccc cgaggggggtg gcccggcgct acggcgggga gtggacggag	1200
25	gaggcggggg agcgggcccgc cctttccgag aggctcttcg ccaacctgtg ggggaggctt	1260
	gagggggagg agaggctcct ttggctttac cgggaggtgg agaggccct ttcgctgtc	1320
	ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc	1380
30	ctggaggtgg ccgaggagat cgcccgcctc gaggcgagg tcttccgcct ggccggccac	1440
	cccttcaacc tcaactcccg ggaccagctg gaaagggtcc tctttgacga gctagggctt	1500
35	cccgccatcg gcaagacgga gaagaccggc aagcgctcca ccagcgccgc cgtcctggag	1560
	gccctccgcg agggccaccc catcgtggag aagatcctgc agtacaagga gctaccaag	1620
	ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac gggccgcctc	1680
40	cacacccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac	1740
	ctccagaaca tccccgtccg caccocgctt gggcagagga tccgcccggc cttcatcgcc	1800
	gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc	1860
45	cacctctccg gcgacgagaa cctgatccgg gtcttccagg agggcgggga catccacag	1920
	gagaccgcca gctggatggt cggcgctccc cgggaggccg tggacccct gatgcgcgg	1980
	gcggccaaga ccatcaactt cggggctctc tacggcatgt cggcccaccg cctctcccag	2040
50	gagctagcca tcccttacga ggaggcccag gccttcattg agcgctactt tcagagcttc	2100
	cccaagggtgc gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg	2160
55	gagaccctct tcggccgccc ccgctacgtg ccagacctag agggccgggt gaagagcgtg	2220
	cgggaggcgg ccgagcgcac ggccttcaac atgcccgtcc agggcaccgc cgccgacctc	2280

EP 3 653 729 A1

```

-----
cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc 2400
5  cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag 2460
    gtggggatag gggaggactg gctctccgcc aaggagtga 2499

    <210> 12
10    <211> 2499
    <212> DNA
    <213> Artificial Sequence

    <220>
15    <223> Taq R660V

    <400> 12

20

25

30

35

40

45

50

55

```

EP 3 653 729 A1

	atgaggggga tgctgcccct ctttgagccc aaggggccggg tcctcctggt ggacggccac	60
	cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg	120
5	gtgcaggcgg tctacggctt cgccaagagc ctctcaagg ccctcaagga ggacggggac	180
	gcggtgatcg tggctcttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg	240
10	tacaaggcgg gccggggccc cagcccgag gactttcccc ggcaactcgc cctcatcaag	300
	gagctggtgg acctcctggg gctggcgcg ctcgagggtcc cgggctacga ggcggacgac	360
	gtcctggcca gcctggccaa gaaggcggaa aaggagggct acgagggtccg catcctcacc	420
15	gccgacaaag acctttacca gtccttttcc gaccgcatcc acgtcctcca ccccgagggg	480
	tacctcatca ccccgccctg gctttgggaa aagtacggcc tgaggcccca ccagtgggcc	540
	gactaccggg ccctgaccgg ggacgaggtcc gacaaccttc ccgggggtcaa gggcatcggg	600
20	gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaaagccct cctcaagaac	660
	ctggaccggc tgaagcccg ccatccgggag aagatcctgg cccacatgga cgatctgaag	720
25	ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggaggtgga cttcgccaaa	780
	aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc	840
	ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc	900
30	ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat	960
	cttctggccc tggccgccc cagggggggc cgggtccacc gggccccga gccttataaa	1020
	gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc	1080
35	ctgaggggaa gccttggcct cccgcccggc gacgaccca tgctcctcgc ctacctcctg	1140
	gacccttcca acaccacccc cgaggggggtg gcccggcgct acggcgggga gtggacggag	1200
40	gaggcggggg agcggggcgc cctttccgag aggtctctcg ccaacctgtg ggggaggctt	1260
	gagggggagg agaggctcct ttggctttac cgggaggtgg agaggccct ttcgctgtc	1320

45

50

55

EP 3 653 729 A1

	ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc	1380
	ctggaggtgg ccgaggagat cggccgcctc gaggccgagg tcttccgcct ggccggccac	1440
5	cccttcaacc tcaactcccg ggaccagctg gaaagggtcc tctttgacga gctagggctt	1500
	cccgccatcg gcaagacgga gaagaccggc aagcgctcca ccagcgccgc cgtcctggag	1560
	gccctccgcg agggccaccc catcgtggag aagatcctgc agtaccggga gctaccaag	1620
10	ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac gggccgcctc	1680
	cacaccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac	1740
15	ctccagaaca tccccgtccg caccgcgtt gggcagagga tccgcccggc cttcatcgcc	1800
	gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc	1860
	cacctctccg gcgacgagaa cctgatccgg gtcttccagg aggggcggga catccacacg	1920
20	gagaccgcca gctggatgtt cggcgtcccc cgggaggccg tggaccccct gatgcgcgtg	1980
	gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag	2040
	gagctagcca tcccttacga ggaggccag gccttcattg agcgctactt tcagagcttc	2100
25	cccaaggtgc gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg	2160
	gagaccctct tcggccgccc cgcctacgtg ccagacctag agggccgggt gaagagcgtg	2220
30	cgggaggcgg ccgagcgcat ggccttcaac atgccgtcc agggcaccgc cgccgacctc	2280
	atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc	2340
	cttcagggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc	2400
35	cggctggcca aggaggtcat ggaggggggtg tatcccctgg ccgtgcccct ggaggtggag	2460
	gtggggatag gggaggactg gctctccgcc aaggagtga	2499

40	<210> 13
	<211> 2499
	<212> DNA
	<213> Artificial Sequence
45	<220>
	<223> Taq R536K/R660V
	<400> 13

50

55

EP 3 653 729 A1

	atgaggggga tgctgcccct ctttgagccc aagggccggg tcctcctggt ggacggccac	60
	cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg	120
5	gtgcaggcgg tctacggctt cgccaagagc ctctcaagg ccctcaagga ggacggggac	180
	gcggtgatcg tggctcttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg	240
	tacaaggcgg gccggggcccc cagccgggag gactttcccc ggcaactcgc cctcatcaag	300
10	gagctggtgg acctcctggg gctggcgcg ctcgaggtcc cgggctacga ggcggacgac	360

15

20

25

30

35

40

45

50

55

EP 3 653 729 A1

	gtcctggcca	gcctggccaa	gaaggcggaa	aaggagggct	acgaggtccg	catcctcacc	420
	gccgacaaag	acctttacca	gtccttttcc	gaccgcatcc	acgtcctcca	ccccgagggg	480
5	tacctcatca	ccccggcctg	gctttgggaa	aagtacggcc	tgaggcccga	ccagtgggcc	540
	gactaccggg	ccctgaccgg	ggacgagtcc	gacaaccttc	ccgggggtcaa	gggcatcggg	600
	gagaagacgg	cgaggaagct	tctggaggag	tgggggagcc	tgggaagccct	cctcaagaac	660
10	ctggaccggc	tgaagcccgc	catccgggag	aagatcctgg	cccacatgga	cgatctgaag	720
	ctctcctggg	acctggccaa	ggtgcgccacc	gacctgcccc	tggaggtgga	cttcgccaaa	780
	aggcgggagc	ccgaccggga	gaggccttagg	gcctttctgg	agaggccttga	gtttggcagc	840
15	ctcctccacg	agttcggcct	tctggaaagc	cccaaggccc	tggaggaggc	cccctggccc	900
	ccgccggaag	gggccttcgt	gggctttgtg	ctttcccgca	aggagcccat	gtgggccgat	960
	cttctggccc	tggccgccgc	cagggggggc	cgggtccacc	gggccccga	gccttataaa	1020
20	gccctcaggg	acctgaagga	ggcgcggggg	cttctcgcca	aagacctgag	cgttctggcc	1080
	ctgaggggaag	gccttggcct	cccgcccgcc	gacgacccca	tgctcctcgc	ctacctcctg	1140
	gacccttcca	acaccacccc	cgaggggggtg	gcccggcgct	acggcgggga	gtggacggag	1200
25	gaggcggggg	agcgggccgc	cctttccgag	aggctcttcg	ccaacctgtg	ggggaggctt	1260
	gagggggagg	agaggctcct	ttggctttac	cgggaggtgg	agaggcccct	ttccgctgtc	1320
	ctggcccaca	tggaggccac	gggggtgcgc	ctggacgtgg	cctatctcag	ggccttgtcc	1380
30	ctggaggtgg	ccgaggagat	cgcccgccctc	gaggccgagg	tcttccgcct	ggccggccac	1440
	cccttcaacc	tcaactcccg	ggaccagctg	gaaaggggtcc	tctttgacga	gctagggctt	1500
35	cccgccatcg	gcaagacgga	gaagaccggc	aagcgctcca	ccagcgccgc	cgctcctggag	1560
	gccctccgcg	aggcccaccc	catcgtggag	aagatcctgc	agtacaagga	gctcaccaag	1620
	ctgaagagca	cctacattga	ccccttgccg	gacctcatcc	accccaggac	gggccgcctc	1680
40	cacacccgct	tcaaccagac	ggccacggcc	acgggcaggc	taagtagctc	cgatcccaac	1740
	ctccagaaca	tccccgtccg	caccccgctt	gggcagagga	tccgcccggc	cttcatcgcc	1800
	gaggaggggt	ggctattggg	ggccctggac	tatagccaga	tagagctcag	ggtgctggcc	1860
45	cacctctccg	gcgacgagaa	cctgatccgg	gtcttccagg	agggcgggga	catccacacg	1920
	gagaccgcca	gctggatggt	cggcgtcccc	cgggaggccg	tggaccccct	gatgcgcgtg	1980
	gcggccaaga	ccatcaactt	cggggtcctc	tacggcatgt	cggcccaccg	cctctcccag	2040
50	gagctagcca	tcccttacga	ggaggcccag	gccttcattg	agcgctactt	tcagagcttc	2100
	cccaaggtgc	gggcctggat	tgagaagacc	ctggaggagg	gcaggaggcg	ggggtacgtg	2160
55	gagaccctct	tcggccgccc	ccgctacgtg	ccagacctag	aggcccgggt	gaagagcgtg	2220
	cgggaggcgg	ccgagcgcat	ggccttcaac	atgcccgctc	agggcacccg	cgccgacctc	2280

EP 3 653 729 A1

	atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc	2340
	cttcagggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc	2400
5	cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag	2460
	gtggggatag gggaggactg gctctccgcc aaggagtga	2499

10	<210> 14
	<211> 2499
	<212> DNA
	<213> Artificial Sequence

15	<220>
	<223> Taq E507K/R536

	<400> 14
--	----------

20

25

30

35

40

45

50

55

EP 3 653 729 A1

	atgaggggga tgctgcccct ctttgagccc aagggccggg tcctcctggt ggacggccac	60
	cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg	120
5	gtgcaggcgg tctacggctt cgccaagagc ctctcaagg ccctcaagga ggacggggac	180
	gcggtgatcg tggctcttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg	240
10	tacaaggcgg gccgggcccc cagccgggag gactttcccc ggcaactcgc cctcatcaag	300
	gagctggtgg acctcctggg gctggcgcg ctcgaggtcc cgggctacga ggcggacgac	360
	gtcctggcca gcctggccaa gaaggcggaa aaggagggtc acgaggtccg catcctcacc	420
15	gccgacaaag acctttacca gctcctttcc gaccgcatcc acgtcctcca ccccgagggg	480
	tacctcatca ccccgccctg gctttgggaa aagtacggcc tgaggcccca ccagtgggcc	540
	gactaccggg ccctgaccgg ggacgagtc gacaaccttc ccgggggtcaa gggcatcggg	600
20	gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaaagccct cctcaagaac	660
	ctggaccggc tgaagcccg ccatccgggag aagatcctgg cccacatgga cgatctgaag	720
25	ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggaggtgga cttcgccaaa	780
	aggcgggagc ccgaccggga gaggttagg gcctttctgg agaggcttga gtttggcagc	840
	ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc	900
30	ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat	960
	cttctggccc tggccgccc cagggggggc cgggtccacc gggccccga gccttataaa	1020
	gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc	1080
35	ctgaggggaa gccttggcct cccgcccggc gacgaccca tgctcctcgc ctacctcctg	1140
	gacccttcca acaccacccc cgaggggggtg gcccggcgct acggcgggga gtggacggag	1200
40	gaggcggggg agcgggccc cctttccgag aggtctctcg ccaacctgtg ggggaggctt	1260
	gagggggagg agaggctcct ttggctttac cgggaggtgg agaggccct ttcgctgtc	1320

45

50

55

EP 3 653 729 A1

	ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc	1380
	ctggaggtgg ccgaggagat cggccgcctc gaggccgagg tcttccgcct ggccggccac	1440
5	cccttcaacc tcaactcccg ggaccagctg gaaaggggtcc tctttgacga gctagggctt	1500
	cccgccatcg gcaagacgaa aaagaccggc aagcgctcca ccagcgccgc cgtcctggag	1560
	gccctccgcg agggccaccc catcgtggag aagatcctgc agtacaagga gctcaccaag	1620
10	ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac gggccgcctc	1680
	cacaccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac	1740
	ctccagaaca tccccgtccg caccgcgtt gggcagagga tccgcggggc cttcatcgcc	1800
	gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc	1860
	cacctctccg gcgacgagaa cctgatccgg gtcttccagg aggggcggga catccacacg	1920
20	gagaccgcca gctggatggt cggcgtcccc cgggaggccg tggaccccct gatgcgccgg	1980
	gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag	2040
	gagctagcca tcccttacga ggaggccag gccttcattg agcgctactt tcagagcttc	2100
25	cccaaggtgc gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg	2160
	gagaccctct tcggccgcgg ccgctacgtg ccagacctag agggccgggt gaagagcgtg	2220
	cgggaggcgg ccgagcgcat ggccttcaac atgccgtcc agggcaccgc cgccgacctc	2280
30	atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc	2340
	cttcagggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc	2400
35	cggctggcca aggaggtcat ggaggggggtg tatcccctgg ccgtgcccct ggaggtggag	2460
	gtggggatag gggaggactg gctctccgcc aaggagtga	2499

40	<210> 15
	<211> 2499
	<212> DNA
	<213> Artificial Sequence
45	<220>
	<223> Taq E507K/R660V
	<400> 15

50

55

EP 3 653 729 A1

	atgaggggga tgctgcccct ctttgagccc aagggccggg tcctcctggt ggacggccac	60
	cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg	120
5	gtgcaggcgg tctacggctt cgccaagagc ctctcaagg ccctcaagga ggacggggac	180
	gcggtgatcg tggctcttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg	240
	tacaaggcgg gccggggcccc cagccgggag gactttcccc ggcaactcgc cctcatcaag	300
10	gagctggtgg acctcctggg gctggcgcg ctcgaggtcc cgggctacga ggcggacgac	360

15

20

25

30

35

40

45

50

55

EP 3 653 729 A1

	gtcctggcca gcctggccaa gaaggcggaa aaggagggct acgaggtccg catcctcacc	420
	gccgacaaaag acctttacca gtccttttcc gaccgcatcc acgtcctcca ccccgagggg	480
5	tacctcatca ccccggcctg gctttgggaa aagtacggcc tgaggcccga ccagtgggcc	540
	gactaccggg ccctgaccgg ggacgagtcc gacaaccttc ccgggggtcaa gggcatcggg	600
	gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaaacct cctcaagaac	660
10	ctggaccggc tgaagccgc catccgggag aagatcctgg ccacatgga cgatctgaag	720
	ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggaggtgga cttcgccaaa	780
	aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc	840
15	ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc	900
	ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat	960
20	cttctggccc tggccgccc cagggggggc cggtccacc gggccccga gccttataaa	1020
	gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc	1080
	ctgaggggaag gccttggcct cccgcccggc gacgaccca tgctcctcgc ctacctcctg	1140
25	gacccttcca acaccacccc cgaggggggtg gcccggcgct acggcgggga gtggacggag	1200
	gaggcggggg agcgggccc ctttccgag aggtcttcg ccaacctgtg ggggaggctt	1260
	gagggggagg agaggctcct ttggctttac cgggaggtgg agaggccct ttcgctgtc	1320
30	ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc	1380
	ctggaggtgg ccgaggagat cggccgcctc gaggccgagg tcttcgcct ggccggccac	1440
35	cccttcaacc tcaactcccg ggaccagctg gaaagggtcc tctttgacga gctagggtt	1500
	cccgccatcg gcaagacgaa aaagaccggc aagcgctcca ccagcgccgc cgtcctggag	1560
	gccctccgcg agggccacc catcgtggag aagatcctgc agtaccggga gctaccaag	1620
40	ctgaagagca cctacattga ccccttgccg gacctcatcc acccaggac gggccgcctc	1680
	cacaccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac	1740
	ctccagaaca tccccgtccg caccgcgtt gggcagagga tccgcccggc cttcatcgcc	1800
45	gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc	1860
	cacctctccg gcgacgagaa cctgatccgg gtcttcagg agggcgggga catccacacg	1920
	gagaccgcca gctggatggt cggcgctccc cgggaggccg tggacccct gatgcgcgtg	1980
50	gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag	2040
	gagctagcca tcccttacga ggaggcccag gccttcattg agcgctactt tcagagcttc	2100
55	cccaagggtg gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg	2160
	gagaccctct tcggccgcg cgcctacgtg ccagacctag agggccgggt gaagagcgtg	2220

EP 3 653 729 A1

	cgggaggcgg ccgagcgcat ggccttcaac atgcccgctc agggcacccg cgccgacctc	2280
	atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc	2340
5	cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc	2400
	cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag	2460
10	gtggggatag gggaggactg gctctccgcc aaggagtga	2499

<210> 16

<211> 2499

<212> DNA

<213> Artificial Sequence

<220>

<223> Taq E507K/R536K/R660V

<400> 16

EP 3 653 729 A1

	atgaggggga tgctgccct ctttgagccc aagggccggg tcctcctggt ggacggccac	60
	cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg	120
5	gtgcaggcgg tctacggctt cgccaagagc ctctcaagg ccctcaagga ggacggggac	180
	gcggtgatcg tgggtcttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg	240
10	tacaaggcgg gccggggccc cagccgggag gactttcccc ggcaactcgc cctcatcaag	300
	gagctggtgg acctcctggg gctggcgcg ctcgagggtcc cgggctacga ggcgacgac	360
	gtcctggcca gcctggccaa gaaggcgga aaggagggt acgagggtccg catcctcacc	420
15	gccgacaaag acctttacca gctcctttcc gaccgcatcc acgtcctcca ccccgagggg	480
	tacctcatca ccccggcctg gctttgggaa aagtacggcc tgaggcccga ccagtgggcc	540
	gactaccggg ccctgaccgg ggacgagtcc gacaaccttc ccggggtcaa gggcatcggg	600
20	gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaagccct cctcaagaac	660
	ctggaccggc tgaagccgc catccgggag aagatcctgg cccacatgga cgatctgaag	720
	ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggagggtgga cttcgccaaa	780
25	aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc	840
	ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc	900
30	ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat	960
	cttctggccc tggccgccc cagggggggc cgggtccacc gggccccga gccttataaa	1020
	gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc	1080
35	ctgaggggaa gccttggcct cccgcccggc gacgaccca tgetcctcgc ctacctcctg	1140
	gacccttcca acaccacccc cgaggggggtg gcccggcgct acggcgggga gtggacggag	1200
40	gaggcggggg agcgggccc cctttccgag aggctcttcg ccaacctgtg ggggaggctt	1260
45		
50		
55		

EP 3 653 729 A1

	gagggggagg agaggctcct ttggctttac cgggaggtgg agaggcccct ttccgctgtc	1320
	ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgctc	1380
5	ctggaggtgg ccgaggagat cgcgcgcctc gagggcgagg tcttccgcct ggccggccac	1440
	cccttcaacc tcaactcccg ggaccagctg gaaaggggtcc tctttgacga gctagggctt	1500
	cccgccatcg gcaagacgaa aaagaccggc aagcgctcca ccagcgccgc cgtcctggag	1560
10	gccctccgcg agggccaccc catcgtggag aagatcctgc agtacaagga gctcaccaag	1620
	ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac ggcccgctc	1680
15	cacaccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac	1740
	ctccagaaca tccccgtccg caccgcgctt gggcagagga tccgcccggc cttcatcgcc	1800
	gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc	1860
20	cacctctccg gcgacgagaa cctgatccgg gtcttccagg agggcgggga catccacacg	1920
	gagaccgcca gctggatggt cggcgctccc cgggaggccg tggaccccct gatgcgcgtg	1980
	gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag	2040
25	gagctagcca tcccttacga ggaggccag gccttcattg agcgctactt tcagagcttc	2100
	cccaaggtgc gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg	2160
30	gagaccctct tcggccgccc ccgctacgtg ccagacctag agggccgggt gaagagcgtg	2220
	cgggaggcgg ccgagcgcat ggccttcaac atgcccgctc agggcaccgc cgccgacctc	2280
	atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc	2340
35	cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc	2400
	cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag	2460
40	gtggggatag gggaggactg gctctccgcc aaggagtga	2499
	<210> 17	
	<211> 20	
	<212> DNA	
	<213> Artificial Sequence	
45	<220>	
	<223> Eco-forward primer	
	<400> 17	
50	ggggtacctc atcaccccg	20
	<210> 18	
	<211> 27	
	<212> DNA	
55	<213> Artificial Sequence	
	<220>	
	<223> R536K-reverse primer	

<400> 18
 cttggtgagc tcctgtact gcaggat 27

 <210> 19
 <211> 27
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> R536K-forward primer

 <400> 19
 atcctgcagt acaaggagct caccaag 27

 <210> 20
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> R660V-reverse primer

 <400> 20
 gatggtcttg gccgccacgc gcatcagggg 30

 <210> 21
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> R660V-forward primer

 <400> 21
 cccctgatgc gcgtagcggc caagaccatc 30

 <210> 22
 <211> 32
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Xba-reverse primer

 <400> 22
 gctctagact atcactcctt ggcggagagc ca 32

 <210> 23
 <211> 27
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> E507K-reverse primer

 <400> 23
 cttgccggtc ttttcgtct tgccgat 27

<210> 24
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> E507K-forward primer
 <400> 24
 10 atcggcaaga cgaaaaagac cggcaag 27
 <210> 25
 <211> 25
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> rs1408799 forward primer
 20 <400> 25
 ccagtgttag gttattcta acttg 25
 <210> 26
 <211> 19
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> rs1408799 reverse_T primer
 30 <400> 26
 gctcggagca catggtcaa 19
 <210> 27
 35 <211> 19
 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> rs1408799 reverse_C primer
 <400> 27
 gctcggagca catggtcag 19
 45 <210> 28
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> rs1015362 forward primer
 <400> 28
 55 tgaagagcag gaaagttctt ca 22
 <210> 29
 <211> 20
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> rsl015362 reverse_C primer
 5
 <400> 29
 actgtgtgtc tgaaacagtg 20
 <210> 30
 10 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> rsl015362 reverse_T primer
 <400> 30
 actgtgtgtc tgaaacagta 20
 20 <210> 31
 <211> 26
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> rs4911414 forward_G primer
 <400> 31
 30 gtaagtcttt gctgagaaat tcattg 26
 <210> 32
 <211> 26
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> rs4911414 forward_T primer
 <400> 32
 40 gtaagtcttt gctgagaaat tcattt 26
 <210> 33
 <211> 23
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <223> rs4911414 reverse primer
 50 <400> 33
 agtatccagg gttaatgtga aag 23
 <210> 34
 <211> 25
 55 <212> DNA
 <213> Artificial Sequence
 <220>

EP 3 653 729 A1

<223> 1408799-FAM probe

<400> 34
agatattgt aaggattct ggcct 25

<210> 35
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> 1015362-HEX probe

<400> 35
tgctgaacaa atagtccga ccag 24

<210> 36
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> 4911414-Texas Red probe

<400> 36
tttcttagt tgccttaag attt 24

<210> 37
<211> 832
<212> PRT
<213> Artificial Sequence

<220>
<223> Taq E507K/R536K/R587I/R660V

<400> 37

Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15

EP 3 653 729 A1

	Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Leu	Lys	Gly	
				20					25					30			
5	Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe	Ala	
				35				40					45				
	Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile	Val	
		50					55					60					
10	Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly	Gly	
	65					70					75					80	
	Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln	Leu	
					85					90					95		
15	Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Leu	Ala	Arg	Leu	Glu	
				100					105					110			
	Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys	Lys	
			115					120					125				
20	Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys	Asp	
		130					135					140					
	Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu	Gly	
	145					150					155					160	
25	Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg	Pro	
					165					170					175		
	Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp	Asn	
				180					185					190			
30	Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu	Leu	
			195					200					205				
	Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Leu	Lys	Asn	Leu	Asp	Arg	Leu	
35		210					215					220					
	Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Leu	Ala	His	Met	Asp	Asp	Leu	Lys	
	225					230					235					240	
40	Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu	Val	
					245					250					255		
	Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala	Phe	
				260					265					270			
45	Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Leu	Leu	His	Glu	Phe	Gly	Leu	Leu	
			275					280					285				
	Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu	Gly	
		290					295					300					
50	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala	Asp	
	305					310					315					320	
	Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	Pro	
					325					330					335		
55	Glu	Pro	Tyr	Lys	Ala	Leu	Arg	Asp	Leu	Lys	Glu	Ala	Arg	Gly	Leu	Leu	
				340					345					350			

EP 3 653 729 A1

	Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu	Pro	
			355					360					365				
5	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser	Asn	
			370				375					380					
	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr	Glu	
						390					395					400	
10	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn	Leu	
					405					410					415		
	Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	Glu	
				420					425					430			
15	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr	Gly	
			435					440					445				
	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val	Ala	
			450				455					460					
20	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly	His	
						470					475					480	
	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe	Asp	
					485				490						495		
25	Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Glu	Lys	Lys	Thr	Gly	Lys	Arg	
				500					505					510			
	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro	Ile	
			515					520					525				
30	Val	Glu	Lys	Ile	Leu	Gln	Tyr	Lys	Glu	Leu	Thr	Lys	Leu	Lys	Ser	Thr	
			530				535					540					
	Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg	Leu	
35						550					555					560	
	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser	Ser	
					565				570						575		
	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Ile	Thr	Pro	Leu	Gly	Gln	
40				580					585					590			
	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val	Ala	
					595			600					605				
45	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser	Gly	
						615						620					
	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His	Thr	
						630					635					640	
50	Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp	Pro	
					645					650					655		
	Leu	Met	Arg	Val	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr	Gly	
				660					665					670			
55	Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu	Glu	
				675				680					685				

EP 3 653 729 A1

	Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg	
	690	695 700
5	Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val	
	705	710 715 720
	Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg	
		725 730 735
10	Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro	
		740 745 750
	Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu	
		755 760 765
15	Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His	
		770 775 780
	Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala	
20		785 790 795 800
	Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro	
		805 810 815
	Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu	
25		820 825 830

<210> 38
 <211> 2499
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Taq E507K/R536K/R587I/R660V

<400> 38

	atgaggggga tgctgccct ctttgagccc aagggccggg tcctcctggt ggacggccac	60
	cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg	120
40	gtgcaggcgg tctacggctt cgccaagagc ctcctcaagg ccctcaagga ggacggggac	180
	gcggtgatcg tgggtcttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg	240
45	tacaaggcgg gccggggccc cagccgggag gactttcccc ggcaactcgc cctcatcaag	300
	gagctggtgg acctcctggg gctggcgcg ctcgaggtcc cgggctacga ggcggacgac	360
	gtcctggcca gcctggccaa gaaggcggaa aaggagggtc acgaggtccg catcctcacc	420
50	gccgacaaag acctttacca gtccttttcc gaccgcatcc acgtcctcca ccccgagggg	480
	tacctcatca cccgggcctg gcttttggaa aagtacggcc tgaggcccga ccagtgggccc	540
	gactaccggg ccctgaccgg ggacgagtc gacaaccttc ccgggggtcaa gggcatcggg	600
55	gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaagccct cctcaagaac	660

EP 3 653 729 A1

	ctggaccggc tgaagccgc catccgggag aagatcctgg cccacatgga cgatctgaag	720
	ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggaggtgga cttcgccaaa	780
5	aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc	840
	ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc	900
	ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat	960
10	cttctggccc tggccgccc cagggggggc cgggtccacc gggccccga gccttataaa	1020
	gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc	1080
	ctgaggggaag gccttggcct cccgcccggc gacgacccca tgctcctcgc ctacctcctg	1140
15	gacccttcca acaccacccc cgaggggggtg gcccggcgct acggcgggga gtggacggag	1200
	gaggcggggg agcgggccgc cttttccgag aggtcttcg ccaacctgtg ggggaggctt	1260
20	gagggggagg agaggctcct ttggctttac cgggaggtgg agaggccct ttcgctgtc	1320
	ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc	1380
	ctggaggtgg ccgaggagat cggccgcctc gaggcggagg tcttccgcct ggccggccac	1440
25	cccttcaacc tcaactcccg ggaccagctg gaaagggtcc tctttgacga gctagggtt	1500
	cccgccatcg gcaagacgaa aaagaccggc aagcgctcca ccagcgccgc cgtcctggag	1560
	gccctccgcg agggccaccc catcgtggag aagatcctgc agtacaagga gctaccaag	1620
30	ctgaagagca cctacattga ccccttgccg gacctcatcc acccaggac gggccgcctc	1680
	cacaccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac	1740
35	ctccagaaca tccccgtcat caccocgctt gggcagagga tccgcgggc cttcatcgcc	1800
	gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc	1860
	cacctctccg gcgacgagaa cctgatccgg gtcttccagg agggcgggga catccacacg	1920
40	gagaccgcca gctggatgtt cggcgtcccc cgggaggccg tggacccct gatgcgcgtg	1980
	gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag	2040
	gagctagcca tcccttacga ggaggcccag gccttcattg agcgctactt tcagagcttc	2100
45	cccaagggtg gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg	2160
	gagaccctct tcggccgcgc cgcctacgtg ccagacctag agggccgggt gaagagcgtg	2220
	cgggaggcgg ccgagcgcat ggccttcaac atgcccgtcc agggcacccg cggcgacctc	2280
50	atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc	2340
	cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agaggcgga ggccgtggcc	2400
55	cggctggcca aggaggtcat ggaggggggtg tatcccctgg ccgtgcccct ggaggtggag	2460
	gtggggatag gggaggactg gctctccgcc aaggagtga	2499

<210> 39
 <211> 36
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Kpn-forward primer
 <400> 39
 10 tccaccccga ggggtacctc atcaccccg cctggc 36
 <210> 40
 <211> 27
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> -forward primer
 20 <400> 40
 cccaagcggg gtgatgacgg ggatgtt 27
 <210> 41
 <211> 27
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> R587I-forward primer
 30 <400> 41
 aacatcccg tcacacccc gcttggg 27
 <210> 42
 35 <211> 37
 <212> DNA
 <213> Artificial Sequence
 <220>
 40 <223> Xba-reverse primer
 <400> 42
 ctgcaggtcg actctagact atcactcctt ggcggag 37
 45 <210> 43
 <211> 24
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> KRAS Q61H forward_Q primer(24mer)
 <400> 43
 55 gatattctcg acacagcagg tcaa 24
 <210> 44
 <211> 24
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> KRAS Q61H forward_H primer(24mer)
 5
 <400> 44
 gatattctcg acacagcagg tcac 24
 <210> 45
 10 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> KRAS Q61H reverse primer
 <400> 45
 acaaagaaag ccctcccag 20
 20 <210> 46
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> KRAS Q61H FAM probe
 <400> 46
 tgcaatgagg gaccagtaca tgagg 25
 30 <210> 47
 <211> 18
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> KRAS Q61H forward_Q primer(18mer)
 <400> 47
 40 ctcgacacag caggtcaa 18
 <210> 48
 <211> 18
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <223> KRAS Q61H forward_H primer(18mer)
 50 <400> 48
 ctcgacacag caggtcac 18
 <210> 49
 <211> 20
 55 <212> DNA
 <213> Artificial Sequence
 <220>

<223> KRAS Q61H reverse primer

<400> 49
 acaaagaaag ccctcccag 20

5

<210> 50
 <211> 21
 <212> DNA
 <213> Artificial Sequence

10

<220>
 <223> KRAS G13D forward primer

<400> 50
 ataaggcctg ctgaaatga c 21

15

<210> 51
 <211> 17
 <212> DNA
 <213> Artificial Sequence

20

<220>
 <223> KRAS G13D reverse_G primer(17mer)

25

<400> 51
 ggcaactcttg cctacgc 17

<210> 52
 <211> 17
 <212> DNA
 <213> Artificial Sequence

30

<220>
 <223> KRAS G13D reverse_D primer(17mer)

35

<400> 52
 ggcaactcttg cctacgt 17

<210> 53
 <211> 30
 <212> DNA
 <213> Artificial Sequence

40

<220>
 <223> G1213_R FAM

45

<400> 53
 agctccaact accacaagtt tatattcagt 30

50

<210> 54
 <211> 23
 <212> DNA
 <213> Artificial Sequence

55

<220>
 <223> KRAS G12S forward_G primer(23mer)

<400> 54

taaacttggtg gtagttggag ctg 23
 <210> 55
 <211> 23
 5 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> KRAS G12S forward_S primer(23mer)
 10
 <400> 55
 taaacttggtg gtagttggag cta 23
 <210> 56
 15 <211> 28
 <212> DNA
 <213> Artificial Sequence
 <220>
 20 <223> KRAS G12S reverse primer
 <400> 56
 catattcgct cacaaaatga ttctgaat 28
 25 <210> 57
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> G1213_F FAM probe
 <400> 57
 35 agctgtatcg tcaaggcact ctgct 25
 <210> 58
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 40 <220>
 <223> EGFR L858R forward primer
 <400> 58
 45 acctggcagc caggaacgta 20
 <210> 59
 <211> 19
 <212> DNA
 50 <213> Artificial Sequence
 <220>
 <223> EGFR L858R reverse_L primer
 55 <400> 59
 gcaccagca gtttgcca 19
 <210> 60

<211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> EGFR L858R reverse_R primer

<400> 60
 gcacccagca gtttgccc 19

<210> 61
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> L858R FAM_R probe

<400> 61
 cagcatgtca agatcacaga tttgggc 28

Claims

1. A DNA polymerase comprising a Taq polymerase amino acid sequence of SEQ ID NO: 1, the DNA polymerase comprising:
 - (a) a substitution at amino acid residue 507 in the amino acid sequence of SEQ ID NO: 1; and
 - (b)
 - (i) a substitution at amino acid residue 536 in the amino acid sequence of SEQ ID NO: 1,
 - (ii) a substitution at amino acid residue 660 in the amino acid sequence of SEQ ID NO: 1,
 - (iii) substitutions at amino acid residues 536 and 660 in the amino acid sequence of SEQ ID NO: 1, or
 - (iv) substitutions at amino acid residues 536, 587 and 660 in the amino acid sequence of SEQ ID NO: 1.
2. The DNA polymerase of claim 1, wherein the substitution at the amino acid residue 507 is a substitution of glutamic acid (E) with lysine (K), the substitution at the amino acid residue 536 is a substitution of arginine (R) with lysine (K), the substitution at the amino acid residue 587 is a substitution of arginine (R) with isoleucine (I), and the substitution at the amino acid residue 660 is a substitution of arginine (R) with valine (V).
3. The DNA polymerase of claim 1, which discriminates the matched primer from the mismatched primer, wherein the matched primer is hybridized with the target sequence, and the mismatched primer has a non-canonical nucleotide at the 3' end thereof with respect to the hybridized target sequence.
4. The DNA polymerase of claim 1, wherein the amplification of the target sequence comprising the matched primer exhibits a Ct value lower than the amplification of the target sequence comprising the mismatched primer.
5. A nucleic acid sequence encoding the DNA polymerase of claim 2.
6. A vector comprising the nucleic acid sequence of claim 5.
7. A host cell transformed with the vector of claim 6.
8. A method of *in vitro* detecting one or more gene variations or SNPs in one or more templates, the method comprising: bringing the DNA polymerase of claim 1 or 2 into contact with a) one or more templates; b) one or more matched primers, one or more mismatched primers or both of one or more matched primers and one or more mismatched primers; and c) a nucleoside triphosphate, wherein the one or more matched primers and the one or more mismatched primers are hybridized with a target sequence, and the mismatched primer has a non-canonical nucleotide at base

position 7 from the 3' end thereof with respect to the hybridized target sequence.

9. The method of claim 8, further comprising analyzing a melting temperature using a double strand-specific dye.

10. The method of claim 8, wherein the method is accomplished by real-time PCR, the analysis on agarose gel after standard PCR, gene variation-specific amplification or allele-specific amplification through real-time PCR, tetra-primer amplification-refractory mutation system PCR or isothermal amplification.

11. A composition for detecting a gene variation or SNP, comprising the DNA polymerase of claim 1 or 2.

12. A PCR kit comprising the composition of claim 11.

13. The PCR kit of claim 12, wherein the PCR kit is used in competitive allele-specific TaqMan PCR (cast PCR), droplet digital PCR or MassARRAY.

14. The PCR kit of claim 12, further comprising one or more matched primers, one or more mismatched primers or both of one or more matched primers and one or more mismatched primers, wherein the one or more matched primers and the one or more mismatched primers are hybridized with a target sequence, and the mismatched primer has a non-canonical nucleotide at base position 7 from the 3' end thereof with respect to the hybridized target sequence.

15. The PCR kit of claim 12, further comprising a nucleoside triphosphate.

16. The PCR kit of claim 12, further comprising:

a) one or more buffers; b) a quantification reagent binding to double-stranded DNA; c) a polymerase blocking antibody; d) one or more control values or control sequences; and e) one or more templates.

17. A PCR buffer composition for increasing the activity of a DNA polymerase with increased gene variation-specific amplification efficiency, the composition comprising:
25 to 100 mM KCl; and 1 to 15 mM $(\text{NH}_4)_2\text{SO}_4$, wherein the final pH is 8.0 to 9.0.

18. The PCR buffer composition of claim 17, wherein the KCl concentration is 60 to 90 mM.

19. The PCR buffer composition of claim 17, wherein the $(\text{NH}_4)_2\text{SO}_4$ concentration is 2.5 to 8 mM.

20. The PCR buffer composition of claim 17, wherein the KCl concentration is 70 to 80 mM, and the $(\text{NH}_4)_2\text{SO}_4$ concentration is 4 to 6 mM.

21. The PCR buffer composition of claim 17, further comprising 5 to 80 mM tetra methyl ammonium chloride (TMAC).

22. The PCR buffer composition of claim 21, wherein the KCl concentration is 40 to 90 mM.

23. The PCR buffer composition of claim 21, wherein the $(\text{NH}_4)_2\text{SO}_4$ concentration is 1 to 7 mM.

24. The PCR buffer composition of claim 21, wherein the TMAC concentration is 15 to 70 mM, the KCl concentration is 50 to 80 mM, and the $(\text{NH}_4)_2\text{SO}_4$ concentration is 1.5 to 6 mM.

25. The PCR buffer composition of claim 17, further comprising Tris·Cl and MgCl_2 .

26. A PCR kit for detecting a gene variation or SNP, comprising the PCR buffer composition of any one of claims 17 to 25.

27. The PCR kit of claim 26, further comprising the following DNA polymerase, which is DNA polymerase comprising a Taq polymerase amino acid sequence of SEQ ID NO: 1, comprising: (a) a substitution at amino acid residue 507 in the amino acid sequence of SEQ ID NO: 1; and (b) (i) a substitution at amino acid residue 536 in the amino acid sequence of SEQ ID NO: 1, (ii) a substitution at amino acid residue 660 in the amino acid sequence of SEQ ID NO: 1, (iii) substitutions at amino acid residues 536 and 660 in the amino acid sequence of SEQ ID NO: 1, or (iv) substitutions at amino acid residues 536, 587 and 660 in the amino acid sequence of SEQ ID NO: 1.

28. The PCR kit of claim 27, wherein the substitution at the amino acid residue 507 is a substitution of glutamic acid

(E) with lysine (K), the substitution at the amino acid residue 536 is a substitution of arginine (R) with lysine (K), the substitution at the amino acid residue 587 is a substitution of arginine (R) with isoleucine (I), and the substitution at the amino acid residue 660 is a substitution of arginine (R) with valine (V).

- 5 **29.** The PCR kit of claim 26, further comprising:
a) a nucleoside triphosphate; b) a quantification reagent binding to double-stranded DNA; c) a polymerase blocking antibody; d) one or more control values or control sequences; and e) one or more templates.
- 10 **30.** A method of *in vitro* detecting one or more gene variations or SNPs in one or more templates by using the PCR kit of claim 26.
- 15 **31.** The method of claim 30, wherein the PCR kit further comprises the following DNA polymerase, which is a DNA polymerase comprising a Taq polymerase amino acid sequence of SEQ ID NO: 1, comprising: (a) a substitution at amino acid residue 507 in the amino acid sequence of SEQ ID NO: 1; and (b) (i) a substitution at amino acid residue 536 in the amino acid sequence of SEQ ID NO: 1, (ii) a substitution at amino acid residue 660 in the amino acid sequence of SEQ ID NO: 1, (iii) substitutions at amino acid residues 536 and 660 in the amino acid sequence of SEQ ID NO: 1, or (iv) substitutions at amino acid residues 536, 587 and 660 in the amino acid sequence of SEQ ID NO: 1.
- 20 **32.** The method of claim 31, wherein the substitution at the amino acid residue 507 is a substitution of glutamic acid (E) with lysine (K), the substitution at the amino acid residue 536 is a substitution of arginine (R) with lysine (K), the substitution at the amino acid residue 587 is a substitution of arginine (R) with isoleucine (I), and the substitution at the amino acid residue 660 is a substitution of arginine (R) with valine (V).

25

30

35

40

45

50

55




FIG. 1

GEL EXTRACTION (1 UL LOADING)




FIG. 2




FIG. 3

GEL EXTRACTION (1 UL LOADING)




FIG. 4




FIG. 5

rs1408799-FAM

E507K




FIG. 6a

rs1408799-FAM

E507K/R536K




FIG. 6b

rs1408799-FAM

E507K/R660V




FIG. 6c

rs1408799-FAM

E507K/R536K/R660V




FIG. 6d

rs1015362-HEX

E507K




FIG. 7a

rs1015362-HEX

E507K/R536K




FIG. 7b

rs1015362-HEX
E507K/R660V




FIG. 7c

rs1015362-HEX
E507K/R536K/R660V




FIG. 7d

rs4911414-TR

E507K




FIG. 8a

rs4911414-TR

E507K/R536K




FIG. 8b

rs4911414-TR
E507K/R660V




FIG. 8c

rs4911414-TR
E507K/R536K/R660V




FIG. 8d





FIG. 9

KRAS Q61H

E507K/R536K/R660V (24mer)




FIG. 10a

KRAS Q61H

E507K/R536K/R587I/R660V (24mer)




FIG. 10b

KRAS Q61H

E507K/R536K/R660V (18mer)




FIG. 10c

KRAS Q61H

E507K/R536K/R587I/R660V (18mer)





FIG. 10d

KRAS G13D

(a) E507K/R536K/R660V



(b) E507K/R536K/R587I/R660V





FIG. 11

KRAS G12S

(a) E507K/R536K/R660V



(b) E507K/R536K/R587I/R660V





FIG. 12

EGFR L858R

(a) E507K/R536K/R660V



(b) E507K/R536K/R587I/R660V




FIG. 13

BUFFER OPTIMIZATION ACCORDING
TO KCL CONCENTRATION

a) E507K




FIG. 14a

BUFFER OPTIMIZATION ACCORDING
TO KCL CONCENTRATION

b) E507K/R536K







FIG. 14b

**BUFFER OPTIMIZATION ACCORDING
TO KCL CONCENTRATION****c) E507K/R660V****FIG. 14c**

BUFFER OPTIMIZATION ACCORDING
TO KCL CONCENTRATION

d) E507K/R536K/R660V






FIG. 14d




FIG. 15




FIG. 16






FIG. 17

E507K/R536K**FIG. 18a**

E507K/R536K/R660V**FIG. 18b**

rs1015362




FIG. 19a

rs4911414




FIG. 19b

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR2018/006246

A. CLASSIFICATION OF SUBJECT MATTER

C12Q 1/686(2018.01)i, C12Q 1/6827(2018.01)i, C12N 9/12(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12Q 1/686; C12N 9/12; C12Q 1/68; C12P 21/06; C12Q 1/6827

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean Utility models and applications for Utility models: IPC as above

Japanese Utility models and applications for Utility models: IPC as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS (KIPO internal) & Key words: Taq polymerase, E507K, R536K, R587I, R660V, KCl, (NH₄)₂SO₄, TMAC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 2554665 A2 (FERMENTAS UAB) 06 February 2013 See abstract; claims 1-19; pages 2, 3, 5, 6, 10-17; and figures 1, 5-8.	1-32
Y	WO 2015-082449 A2 (UNIVERSITAET KONSTANZ) 11 June 2015 See claims 1-10, 36; pages 7, 8, 21, 59-63, 70-79; and figures 1-8.	1-32
Y	AllianceBio, Buffer Optimization Kit, Cat. No.: M061RB33 (2007) See first page.	17-32
Y	UGOZZOLI, Luis et al., "Application of an Allele-specific Polymerase Chain Reaction to the Direct Determination of ABO Blood Group Genotypes", Genomics, 1992, vol. 12, no. 4, pages 670-674 See pages 672, 673.	21-24
A	US 2009-0191560 A1 (CHATTERJEE, Deb K.) 30 July 2009 See the entire document.	1-32

☐ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

07 SEPTEMBER 2018 (07.09.2018)

Date of mailing of the international search report

07 SEPTEMBER 2018 (07.09.2018)

Name and mailing address of the ISA/KR



Korean Intellectual Property Office
Government Complex Daejeon Building 4, 189, Cheongsu-ro, Seo-gu,
Daejeon, 35208, Republic of Korea
Facsimile No. +82-42-481-8578

Authorized officer

Telephone No.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/KR2018/006246

Patent document cited in search report	Publication date	Patent family member	Publication date
EP 2554665 A2	06/02/2013	EP 2554665 A3	06/03/2013
		EP 2554665 B1	16/09/2015
		EP 3026111 A2	01/06/2016
		EP 3026111 A3	31/08/2016
		EP 3026111 B1	06/06/2018
		US 2013-0034879 A1	07/02/2013
		US 2017-0081646 A1	23/03/2017
		US 9493848 B2	15/11/2016
WO 2015-082449 A2	11/06/2015	ZA 201205891 B	28/01/2015
		CA 2930875 A1	11/06/2015
		EP 3077532 A2	12/10/2016
		LU 92320 A1	03/06/2015
		US 2016-0298174 A1	13/10/2016
		WO 2015-082449 A3	27/08/2015
US 2009-0191560 A1	30/07/2009	AU 7236296 A	27/03/1997
		CA 2174944 A1	11/04/1996
		DE 69531660 D1	09/10/2003
		EP 0725827 A1	08/10/2003
		EP 0725827 B1	03/09/2003
		EP 0871775 A1	25/06/2003
		EP 1361275 A1	12/11/2003
		JP 09-506783 A	08/07/1997
		JP 2000-502882 A	14/03/2000
		US 2003-0027296 A1	06/02/2003
		US 2003-0092018 A1	15/05/2003
		US 2003-0162201 A1	28/08/2003
		US 2005-0112637 A1	26/05/2005
		US 2009-0155775 A1	18/06/2009
		US 2011-0250672 A1	13/10/2011
		US 2012-0184017 A1	19/07/2012
		US 5912155 A	15/06/1999
		US 5939301 A	17/08/1999
		US 5948614 A	07/09/1999
		US 6015668 A	18/01/2000
		US 6444424 B1	03/09/2002
		US 6506560 B1	14/01/2003
		WO 96-10640 A1	11/04/1996
		WO 97-09451 A1	13/03/1997

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5595890 A [0007]
- US 5521301 A [0007]
- US 5639611 A [0007]
- US 5496699 A [0009]

Non-patent literature cited in the description

- GUT. *Hum. Mutat*, 2001, vol. 17, 475-492 [0005]